Pyrrolidine derivatives as factor xa inhibitors

ABSTRACT

The invention relates to compounds of formula (I)  
                 
processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.

FIELD OF THE INVENTION

The present invention relates to a novel class of chemical compounds, toprocesses for their preparation, to pharmaceutical compositionscontaining them and to their use in medicine, particularly use in theamelioration of a clinical condition for which a Factor Xa inhibitor isindicated.

BACKGROUND OF THE INVENTION

Factor Xa is a member of the trypsin-like serine protease class ofenzymes. It is a key enzyme in the coagulation cascade. A one-to-onebinding of Factors Xa and Va with calcium ions and phospholipid convertsprothrombin into thrombin. Thrombin plays a central role in themechanism of blood coagulation by converting the soluble plasma protein,fibrinogen, into insoluble fibrin. The insoluble fibrin matrix isrequired for the stabilisation of the primary hemostatic plug. Manysignificant disease states are related to abnormal hemostasis. Withrespect to the coronary arterial vasculature, abnormal thrombusformation due to the rupture of an established atherosclerotic plaque isthe major cause of acute myocardial infarction and unstable angina. Bothtreatment of an occlusive coronary thrombus by thrombolytic therapy andpercutaneous transluminal coronary angioplasty (PTCA) are oftenaccompanied by an acute thrombotic reclosure of the affected vesselwhich requires immediate resolution. With respect to the venousvasculature, a high percentage of patients undergoing major surgery inthe lower extremities or the abdominal area suffer from thrombusformation in the venous vasculature which can result in reduced bloodflow to the affected extremity and a pre-disposition to pulmonaryembolism. Disseminated intravascular coagulopathy commonly occurs withinboth vascular systems during septic shock, certain viral infections andcancer and is characterised by the rapid consumption of coagulationfactors and systemic coagulation which results in the formation oflife-threatening thrombi occurring throughout the vasculature leading towidespread organ failure.

Beyond its direct role in the formation of fibrin rich blood clots,thrombin has been reported to have profound bioregulatory effects on anumber of cellular components within the vasculature and blood, (Shuman,M. A., Ann. NY Acad. Sci., 405: 349 (1986)).

A Factor Xa inhibitor may be useful in the treatment of acute vasculardiseases such as coronary thrombosis (for example myocardial infarctionand unstable angina), thromboembolism, acute vessel closure associatedwith thrombolytic therapy and percutaneous transluminal coronaryangioplasty, transient ischemic attacks, pulmonary embolism, deep veinthrombosis, peripheral arterial occlusion, prevention of vessel luminalnarrowing (restenosis), and the prevention of thromboembolic eventsassociated with atrial fibrillation, e.g. stroke. They may also haveutility as anti-coagulant agents both in-vivo and ex-vivo, and in oedemaand inflammation. Thrombin has been reported to contribute to lungfibroblast proliferation, thus, Factor Xa inhibitors could be useful forthe treatment of some pulmonary fibrotic diseases. Factor Xa inhibitorscould also be useful in the treatment of tumour metastasis, preventingthe fibrin deposition and metastasis caused by the inappropriateactivation of Factor Xa by cysteine proteinases produced by certaintumour cells. Thrombin can induce neurite retraction and thus Factor Xainhibitors may have potential in neurogenerative diseases such asParkinson's and Alzheimer's disease. They have also been reported foruse in conjunction with thrombolytic agents, thus permitting the use ofa lower dose of thrombolytic agent.

The present invention provides novel Factor Xa inhibitors. Compounds ofthe present invention have oral bioavailability and PK profiles suitablefor acute and chronic therapies.

SUMMARY OF THE INVENTION

The present invention provides compounds of formula (I):

wherein:

-   R¹ represents hydrogen, —C₁₋₆alkyl, —C₃₋₆alkenyl,    —C₂₋₃alkylNR^(b)R^(c), —C₂₋₃alkylNHCOR^(b), phenyl or a 5- or    6-membered aromatic heterocyclic group, the phenyl or 5- or    6-membered aromatic heterocyclic group being optionally substituted    by halogen, or R¹ represents a group X—W, wherein X represents    —C₁₋₃alkylene- and W represents —CN, —CO₂H, —CONR^(b)R^(c),    —COC₁₋₆alkyl, —CO₂C₁₋₆alkyl, phenyl or 5- or 6-membered aromatic or    non-aromatic heterocyclic group containing at least one heteroatom    selected from O, N or S, the phenyl or aromatic heterocyclic group    being optionally substituted by one or more substitutents selected    from: —C₁₋₃alkyl, —C₁₋₃alkoxy, —C₁₋₃alkylOH, halogen, —CN, —CF₃,    —NH₂, —CO₂H and —OH;-   R² and R³ independently represent hydrogen, —C₁₋₃alkyl or —CF₃ with    the proviso that one of R² and R³ is —C₁₋₃alkyl or —CF₃ and the    other is hydrogen;-   R^(b) and R^(c) independently represent hydrogen or —C₁₋₃alkyl;

A represents a group selected from:

-   Z represents one or two optional substituents independently selected    from halogen and OH,-   W represents an optional substituent —C₁₋₃alkyl,-   alk represents C₂₋₃alkylene or C₂₋₃alkenylene,-   T represents a heteroatom selected from O, S or N;-   B represents one or more optional substituents on ring carbon atoms    selected from: (i) one or more substituents selected from —CF₃, —F,    —CO₂H, —C₁₋₆alkyl, —C₁₋₆alkylOH, —(C₁₋₃alkyl)NR^(b)R^(c),    —(C₀₋₃alkyl)CONR^(b)R^(c) and —(C₀₋₃alkyl)CO₂C₁₋₃alkyl,    —CONHC₂₋₃alkylOH, —CH₂NHC₂₋₃alkylOH, —CH₂OC₁₋₃alkyl and    —CH₂SO₂C₁₋₃alkyl;-   (ii) a group —Y—R^(e).-   Y represents —C₁₋₃alkylene-, —CO—, —C₁₋₃alkylNH—, —C₁₋₃alkylNHCO—,    —C₁₋₃alkylNHSO₂—, —CH₂NHSO₂CH₂— or a direct link,-   R⁸ represents phenyl, a 5- or 6-membered cycloalkyl or a 5- or    6-membered heterocycle containing at least one heteroatom selected    from O, N or S, each of which is optionally substituted by one or    more substituents selected from: —C₁₋₃alkyl, —C₁₋₃alkoxy,    —C₁₋₃alkylOH, halogen, —CN, —CF₃, —NH₂, —CO₂H and —OH; or-   (iii) a second ring R^(f) which is fused to the heterocyclic ring,    wherein R^(f) represents phenyl, a 5- or 6-membered cycloalkyl group    or a 5- or 6-membered aromatic heterocyclic group containing at    least one heteroatom selected from O, N or S, and the fused bicyclic    group is optionally substituted by one or more substituents selected    from: —C₁₋₃alkyl, —C₁₋₃alkoxy, —C₁₋₃alkylOH, halogen, —CN, —CF₃,    —NH₂, —CO₂H and —OH;-   and pharmaceutically acceptable derivatives thereof.

Further aspects of the invention are:

-   -   A pharmaceutical composition comprising a compound of the        invention together with a pharmaceutical carrier and/or        excipient.    -   A compound of the invention for use in therapy.    -   Use of a compound of the invention for the manufacture of a        medicament for the treatment of a patient suffering from a        condition susceptible to amelioration by a Factor Xa inhibitor.    -   A method of treating a patient suffering from a condition        susceptible to amelioration by a Factor Xa inhibitor comprising        administering a therapeutically effective amount of a compound        of the invention.

DETAILED DESCRIPTION OF THE INVENTION

The present invention also provides compounds of formula (Ia):

wherein:

-   R¹ represents hydrogen, —C₁₋₆alkyl, —C₂₋₆alkenyl or a group X—W,    wherein X represents —C₁₋₃alkylene- and W represents —CN, —CO₂H,    —CONR^(b)R^(c), —COC₁₋₆alkyl, —CO₂C₁₋₆alkyl, phenyl or 5- or    6-membered aromatic heterocyclic group containing at least one    heteroatom selected from O, N or S, the phenyl or aromatic    heterocyclic group being optionally substituted by one or more    substitutents selected from: —C₁₋₃alkyl, —C₁₋₃alkoxy, —C₁₋₃alkylOH,    halogen, —CN, —CF₃, —NH₂, —CO₂H and —OH;-   R² and R³ independently represent hydrogen, —C₁₋₃alkyl or —CF₃ with    the proviso that when one of R² and R³ is —C₁₋₃alkyl or —CF₃, the    other is hydrogen;-   R^(b) and R^(c) independently represent hydrogen or —C₁₋₃alkyl;

A represents a group selected from:

-   Z represents an optional substituent halogen,-   alk represents alkylene or alkenylene,-   T represents a heteroatom selected from S or N;-   B represents one or more optional substituents on ring carbon atoms    selected from: (i) one or more substituents selected from —CF₃, —F,    ═O, —CO₂H, —C₁₋₆alkyl, —C₁₋₆alkylOH, —(C₁₋₃alkyl)NR^(b)R^(c),    —(C₀₋₃alkyl)CONR^(b)R^(c) and —(C₀₋₃alkyl)CO₂C₁₋₃alkyl;-   (ii) a group —Y—R^(e),-   Y represents —C₁₋₃alkylene-, —CO—, —C₁₋₃alkylNH—, —C₁₋₃alkylNHCO—,    —C₁₋₃alkylNHSO₂—, —CH₂NHSO₂CH₂— or a direct link,-   R^(e) represents phenyl, a 5- or 6-membered cycloalkyl or a 5- or    6-membered heterocycle containing at least one heteroatom selected    from O, N or S, each of which is optionally substituted by one or    more substituents selected from: —C₁₋₃alkyl, —C₁₋₃alkoxy,    —C₁₋₃alkylOH, halogen, —CN, —CF₃, —NH₂, —CO₂H and —OH; or-   (iii) a second ring R^(f) which is fused to the heterocyclic ring,    wherein R^(f) represents phenyl, a 5- or 6-membered cycloalkyl group    or a 5- or 6-membered aromatic heterocyclic group containing at    least one heteroatom selected from O, N or S, and the fused bicyclic    group is optionally substituted by one or more substituents selected    from: —C₁₋₃alkyl, —C₁₋₃alkoxy, —C₁₋₃alkylOH, halogen, —CN, —CF₃,    —NH₂, —CO₂H and —OH;-   and pharmaceutically acceptable salts of solvates thereof.

The compounds of formula (I) and (Ia) contain chiral (asymmetric)centres. The individual stereoisomers (enantiomers and diastereoisomers)and mixtures of these are within the scope of the present invention.

When R¹ represents a group X—W:

Preferably, X represents —C₁₋₃alkylene-, more preferably -methylene-.

Preferably, W represents —CN, —CO₂H, —CONR^(b)R^(c), —COC₁₋₆alkyl,—CO₂C₁₋₆alkyl or a 5- or 6-membered aromatic heterocyclic groupcontaining at least one heteroatom selected from O, N or S. Preferably,R¹ represents hydrogen, —C₁₋₆alkyl, —C₂₋₆alkenyl or a group X—W whereinX represents —C₁₋₃alkylene- and W represents —CN, —CO₂H, —CONR^(b)R^(c),—COC₁₋₃alkyl, —CO₂C₁₋₆alkyl or a 5- or 6-membered aromatic heterocyclicgroup containing at least one heteroatom selected from O, N or S. Morepreferably, R¹ represents a group selected from hydrogen, —CH₂CN,—CH₂CONH₂, —CH₂COC₁₋₆alkyl and —CH₂CO₂C₁₋₆alkyl.

In another prefered aspect, R¹ represents hydrogen, —C₁₋₆alkyl,—C₃₋₆alkenyl, —C₂₋₃alkylNR^(b)R^(c), —C₂₋₃alkylNHCOR^(b), phenyl or a 5-or 6-membered aromatic heterocycle, or R¹ represents a group X—W whereinX represents —C₁₋₃alkylene- and W represents —CN, —CO₂H, —CONR^(b)R^(c),—COC₁₋₆alkyl, —CO₂C₁₋₆alkyl, or a 5- or 6-membered aromatic ornon-aromatic heterocyclic group containing at least one heteroatomselected from O, N or S. More preferably, R¹ represents hydrogen,—C₁₋₆alkyl, —C₃₋₆alkenyl, —C₂₋₃alkylNR^(b)R^(c), —C₂₋₃alkylNHCOR^(b), orR¹ represents a group X—W wherein X represents —C₁₋₃alkylene- and Wrepresents —CN, —CO₂H, —CONR^(b)R^(c), —COC₁₋₆alkyl, —CO₂C₁₋₆alkyl, or a5- or 6-membered aromatic or non-aromatic heterocyclic group containingat least one heteroatom selected from O, N or S. Even more preferably,R¹ represents a group selected from: hydrogen, —C₁₋₆alkyl, —CH₂CH═CH₂,—CH₂CH₂N(CH₃)₂, —CH₂CH₂NHCOCH₃, —CH₂CN, —CH₂CO₂H, —CH₂CO₂CH₃,—CH₂CO₂t-Butyl, —CH₂CONH₂, —CH₂COCH₂CH₃, —CH₂COt-Butyl, —CH₂CO₂CH₂CH₃,

Preferably, R² represents —C₁₋₃alkyl or hydrogen, more preferably methylor hydrogen.

Preferably, R³ represents —C₁₋₃alkyl or hydrogen, more preferably methylor hydrogen.

Preferably B represents hydrogen or a substituent selected from—C₁₋₆alkyl, —(C₁₋₃alkyl)NR^(b)R^(c), —(C₀₋₃alkyl)CONR^(b)R^(c),—CONHC₂₋₃alkylOH, —CH₂NHC₂₋₃alkylOH, —CH₂OC₁₋₃alkyl and —CH₂SO₂C₁₋₃alkylor a group —Y—R^(e) where Y represents —CO— or —CH₂— and R^(e)represents a 5- or 6-membered heterocycle containing at least oneheteroatom selected from O, N, S. Preferably, the substitution is in the2-position relative to the oxygen atom in the morpholine ring. Morepreferably, B represents hydrogen or a substituent selected from—C₁₋₆alkyl, —CONHCH₃, —CONHCH₂CH(OH)CH₃, —CH₂NH(CH₃)₂, —CH₂OCH₃,—CH₂SO₂CH₃, —CH₂NHCH₂CH(OH)CH₃,

Even more preferably, B represents hydrogen or methyl. Most preferably Brepresents hydrogen.

Preferably Z represents halogen. More preferably, Z represents chlorine.

Preferably, A represents a substituent selected from:

More preferably, A represents a substituent selected from:

Even more preferably, A represent a substituent selected from:

Most preferably, A represents (chlorothienyl)ethene.

In another preferred aspect of the invention, A representschloronaphthylene, chlorobenzothiophene, chlorobithiophene orchlorophenylethene. More preferably, A represents a group selected from:6-chloronaphthyl, 5′-chloro-2,2′-biothiophene, (4-chlorophenyl)ethene,6-chloro-1-benzothiophene.

It is to be understood that the present invention covers allcombinations of preferred groups described hereinabove.

Hence, in a preferred aspect the present invention provides compounds offormula (Ia) wherein:

-   R¹ represents hydrogen, —C₁₋₆alkyl, —C₃₋₆alkenyl,    —C₂₋₃alkylNR^(b)R^(c), —C₂₋₃alkylNHCOR^(b), phenyl or a 5- or    6-membered aromatic heterocycle, or a group X—W wherein X represents    —C₁₋₃alkylene- and W represents —CN, —CO₂H, —CONR^(b)R^(c),    —COC₁₋₆alkyl, —CO₂C₁₋₆alkyl, or a 5- or 6-membered aromatic or    non-aromatic heterocyclic group containing at least one heteroatom    selected from O, N or S;-   R² and R³ independently represent hydrogen or —C₁₋₃alkyl with the    proviso that one of R² and-   R³ is —C₁₋₃alkyl and the other is hydrogen;-   R^(b) and R^(c) independently represent hydrogen or —C₁₋₃alkyl;-   B represents hydrogen or a substituent selected from —C₁₋₆alkyl,    —(C₁₋₃alkyl)NR^(b)R^(c), —(C₀₋₃alkyl)CONR^(b)R^(c),    —CONHC₂₋₃alkylOH, —CH₂NHC₂₋₃alkylOH, —CH₂OC₁₋₃alkyl and    —CH₂SO₂C₁₋₃alkyl or a group —Y—R^(e) where Y represents —CO— or    —CH₂— and R^(e) represents a 5- or 6-membered heterocycle containing    at least one heteroatom selected from O, N, S.

A represents:

and pharmaceutically acceptable derivatives thereof.

In a more preferred aspect the present invention provides compounds offormula (Ia) wherein:

-   R¹ represents hydrogen, —C₁₋₆alkyl, —C₃₋₆alkenyl,    —C₂₋₃alkylNR^(b)R^(c), —C₂₋₃alkylNHCOR^(b), or a group X—W wherein X    represents —C₁₋₃alkylene- and W represents —CN, —CO₂H,    —CONR^(b)R^(c), —COC₁₋₆alkyl, —CO₂C₁₋₆alkyl, or a 5- or 6-membered    aromatic or non-aromatic heterocyclic group containing at least one    heteroatom selected from O, N or S;-   R² and R³ independently represent hydrogen or —C₁₋₃alkyl with the    proviso that one of R² and-   R³ is —C₁₋₃alkyl and the other is hydrogen;-   B represents hydrogen or a substituent selected from —C₁₋₆alkyl,    —CONHCH₃, —CONHCH₂CH(OH)CH₃, —CH₂NH(CH₃)₂, —CH₂OCH₃, —CH₂SO₂CH₃,    —CH₂NHCH₂CH(OH)CH₃,

A represents a group selected from:

and pharmaceutically acceptable derivatives thereof.

As used herein, the terms “alkyl” and “alkoxy” mean both straight andbranched chain saturated hydrocarbon groups. Examples of alkyl groupsinclude methyl (—CH₃), ethyl (—C₂H₂), propyl (—C₃H₇) and butyl (—C₄H₉).Examples of alkoxy groups include methoxy (—OCH₃) and ethoxy (—OC₂H₅).

As used herein, the term “alkylene” means both straight and branchedchain saturated hydrocarbon linker groups. Examples of alkylene groupsinclude methylene (—CH₂—) and ethylene (—CH₂CH₂—).

As used herein, the term “alkenyl” means both straight and branchedchain unsaturated hydrocarbon groups, wherein the unsaturation ispresent only as double bonds. Examples of alkenyl groups include ethenyl(—CH═CH₂) and propenyl (—CH═CHCH₃ or —CH₂CH═CH₂).

As used herein, the term “alkenylene” means both straight and branchedchain unsaturated hydrocarbon linker groups, wherein the unsaturation ispresent only as double bonds. Examples of alkenylene groups includesethenylene (—CH═CH—) and propenylene (—CH₂—CH═CH— or —CH═CH—CH₂—).

As used herein, the term “alkynyl” means both straight and branchedchain unsaturated hydrocarbon groups, wherein the unsaturation ispresent only as triple bonds. Examples of alkynyl groups includepropynyl (e.g. —CH₂—C≡CH).

As used herein, the term “halogen” means fluorine, chlorine, bromine andiodine.

As used herein, the term “cycloalkyl group” means an aliphatic ring(saturated carbocyclic ring). Examples of cycloalkyl groups includecyclopentyl and cyclohexyl.

As used herein, the term “heterocyclic group” means a ring containingone or more heteroatoms selected from: nitrogen, sulphur and oxygenatoms. The heterocycle may be aromatic or non-aromatic, i.e., may besaturated, partially or fully unsaturated. Examples of 5-membered groupsinclude thienyl, pyrrolyl, pyrrolidinyl, pyrazolyl, imidazolyl,triazolyl, tetrazolyl, thiazolyl, thiadiazolyl, oxazolyl, oxadiazolyl,isoxazolyl and furanyl, 6-membered groups include pyridyl, pyrazyl andpyrimidyl, morpholinyl, thiomorpholinyl, 7-membered groups includeazepinyl.

As used herein, the term “pharmaceutically acceptable” means a compoundwhich is suitable for pharmaceutical use.

As used herein, the term “pharmaceutically acceptable derivative”, meansany pharmaceutically acceptable salt, solvate, or prodrug e.g. ester orcarbamate, or salt or solvate of such a prodrug, of a compound offormula (I) or (Ia), which upon administration to the recipient iscapable of providing (directly or indirectly) a compound of formula (I)or (Ia), or an active metabolite or residue thereof. Preferredpharmaceutically acceptable derivatives are salts and solvates.

Suitable salts according to the invention include those formed with bothorganic and inorganic acids and bases. Pharmaceutically acceptable acidaddition salts include those formed from mineral acids such as:hydrochloric, hydrobromic, sulphuric, phosphoric, acid; and organicacids such as: citric, tartaric, lactic, pyruvic, acetic,trifluoroacetic, succinic, oxalic, formic, fumaric, maleic, oxaloacetic,methanesulphonic, ethanesulphonic, p-toluenesulphonic, benzenesulphonicand isethionic acids. Pharmaceutically acceptable base salts includeammonium salts, alkali metal salts such as those of sodium andpotassium, alkaline earth metal salts such as those of calcium andmagnesium and salts with organic bases, including salts of primary,secondary and tertiary amines, such as isopropylamine, diethylamine,ethanolamine, trimethylamine, dicyclohexyl amine andN-methyl-D-glucamine. Particularly preferred pharmaceutically acceptablesalts include those formed from hydrochloric, trifluoroacetic and formicacids.

Those skilled in the art of organic chemistry will appreciate that manyorganic compounds can form complexes with solvents in which they arereacted or from which they are precipitated or crystallized. Thesecomplexes are known as “solvates”. For example, a complex with water isknown as a “hydrate”. Solvates of the compound of formula (I) or (Ia)are within the scope of the invention.

Salts and solvates of compounds of formula (I) or (Ia) which aresuitable for use in medicine are those wherein the counterion orassociated solvent is pharmaceutically acceptable. However, salts andsolvates having non-pharmaceutically acceptable counterions orassociated solvents are within the scope of the present invention, forexample, for use as intermediates in the preparation of other compoundsof formula (I) or (Ia) and their pharmaceutically acceptable salts andsolvates.

As used herein, the term “prodrug” means a compound which is convertedwithin the body, e.g. by hydrolysis in the blood, into its active formthat has medical effects. Pharmaceutically acceptable prodrugs aredescribed in T. Higuchi and V. Stella, Prodrugs as Novel DeliverySystems, Vol. 14 of the A.C.S. Symposium Series, and in Edward B. Roche,ed., Bioreversible Carriers in Drug Design, American PharmaceuticalAssociation and Pergamon Press, 1987, both of which are incorporatedherein by reference. Esters may be active in their own right and/or behydrolysable under in vivo conditions in the human body. Suitablepharmaceutically acceptable in vivo hydrolysable ester groups includethose which break down readily in the human body to leave the parentacid or its salt.

Preferred compounds of the invention include:

-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-2-(2,6-dimethylmorpholin-4-yl)-1-methyl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-(3-methylmorpholin-4-yl)-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   6-Chloro-N-((3S)-1-{(1S)-1-methyl-2-oxo-2-[3-(pyrrolidin-1-ylcarbonyl)morpholin-4-yl]ethyl}-2-oxopyrrolidin-3-yl)naphthalene-2-sulfonamide,-   6-Chloro-N-[(3S)-1-((1S)-1-methyl-2-{2-[(methylsulfonyl)methyl]morpholin-4-yl}-2-oxoethyl)-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide,-   6-Chloro-N-((3S)-1-{(1S)-2-[2-(methoxymethyl)morpholin-4-yl]-1-methyl-2-oxoethyl}-2-oxopyrrolidin-3-yl)naphthalene-2-sulfonamide,-   4-[(2S)-2-((3S)-3-{[(6-Chloro-2-naphthyl)sulfonyl]amino}-2-oxopyrrolidin-1-yl)propanoyl]-N-methylmorpholine-2-carboxamide,-   6-Chloro-N-((3S)-1-{(1S)-1-methyl-2-oxo-2-[2-(pyrrolidin-1-ylcarbonyl)morpholin-4-yl]ethyl}-2-oxopyrrolidin-3-yl)naphthalene-2-sulfonamide,-   4-[(2S)-2-((3S)-3-{[(6-Chloro-2-naphthyl)sulfonyl]amino}-2-oxopyrrolidin-1-yl)propanoyl]-N,N-dimethylmorpholine-2-carboxamide,-   4-[(2S)-2-((3S)-3-{[(6-Chloro-2-naphthyl)sulfonyl]amino}-2-oxopyrrolidin-1-yl)propanoyl]-N-(2-hydroxypropyl)morpholine-2-carboxamide,-   4-[(2S)-2-((3S)-3-{[(6-Chloro-2-naphthyl)sulfonyl]amino}-2-oxopyrrolidin-1-yl)propanoyl]-N,N-diisopropylmorpholine-2-carboxamide,-   6-Chloro-N-((3S)-1-{(1S)-1-methyl-2-oxo-2-[2-(piperidin-1-ylcarbonyl)morpholin-4-yl]ethyl}-2-oxopyrrolidin-3-yl)naphthalene-2-sulfonamide,-   6-Chloro-N-[(3S)-1-((1S)-1-methyl-2-{2-[(methylamino)methyl]morpholin-4-yl}-2-oxoethyl)-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide    formate,-   6-Chloro-N-((3S)-1-{(1S)-1-methyl-2-oxo-2-[2-(pyrrolidin-1-ylmethyl)morpholin-4-yl]ethyl}-2-oxopyrrolidin-3-yl)naphthalene-2-sulfonamide    formate,-   6-Chloro-N-{(3S)-1-[(1S)-2-(2-{[(2-hydroxypropyl)amino]methyl}morpholin-4-yl)-1-methyl-2oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide    formate,-   6-Chloro-N-[(3S)-1-((1S)-2-{2-[(dimethylamino)methyl]morpholin-4-yl}-1-methyl-2-oxoethyl)-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide    formate,-   6-Chloro-N-[(3S)-1-((1S)-2-{2-[(diisopropylamino)methyl]morpholin-4-yl}-1-methyl-2-oxoethyl)-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide    formate,-   6-Chloro-N-((3S)-1-{(1S)-1-methyl-2-oxo-2-[2-(piperidin-1-ylmethyl)morpholin-4-yl]ethyl}-2-oxopyrrolidin-3-yl)naphthalene-2-sulfonamide    formate,-   6-Chloro-N-((3S)-1-{(1S)-2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-1-methyl-2-oxoethyl}-2-oxopyrrolidin-3-yl)naphthalene-2-sulfonamide,-   6-Chloro-N-{(3R)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   5′-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-2,2′-bithiophene-5-sulfonamide,-   (E)-2-(4-Chlorophenyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide,-   N2-{[(E)-2-(4-Chlorophenyl)ethenyl]sulfonyl}-N2-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinamide,-   N2-[(5′-Chloro-2,2′-bithien-5-yl)sulfonyl]-N2-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinamide,-   5′-Chloro-N-(cyanomethyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-2,2′-bithiophene-5-sulfonamide,-   Methyl    N-[(5′-chloro-2,2′-bithien-5-yl)sulfonyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinate,-   5′-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morphoin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-oxobutyl)-2,2′-bithiophene-5-sulfonamide,-   N-[(5′-Chloro-2,2′-bithien-5-yl)sulfonyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycine,-   (E)-2-(4-Chlorophenyl)-N-(cyanomethyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide,-   (E)-2-(4-Chlorophenyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-oxobutyl)ethenesulfonamide,-   Methyl    N-{[(E)-2-(4-chlorophenyl)ethenyl]sulfonyl}-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinate,-   N-{[(E)-2-(4-Chlorophenyl)ethenyl]sulfonyl}-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycine,-   6-Chloro-N-(3-furylmethyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(pyridin-3-ylmethyl)naphthalene-2-sulfonamide    formate,-   6-Chloro-N-ethyl-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-oxobutyl)naphthalene-2-sulfonamide,-   N-2-[(6-Chloro-2-naphthyl)sulfonyl]-N-2-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinamide,-   6-Chloro-N-(2-furylmethyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(1,3-thiazol-2-ylmethyl)naphthalene-2-sulfonamide,-   N2-[(6-Chloro-2-naphthyl)sulfonyl]-N2-((3S)-1-{(1S)-2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-1-methyl-2-oxoethyl}-2-oxopyrrolidin-3-yl)glycinamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-[(2-methyl-1,3-thiazol-4-yl)methyl]naphthalene-2-sulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(pyridin-2-ylmethyl)naphthalene-2-sulfonamide    formate,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(pyridin-4-ylmethyl)naphthalene-2-sulfonamide    formate,-   6-Chloro-N-{(3S)-1-[(1R)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   6-Chloro-N-methyl-N-{(3S)-1-[(1R)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   6-Chloro-N-(cyanomethyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   6-Chloro-N-methyl-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   6-Chloro-N-(3,3-dimethyl-2-oxobutyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   N2-[(6-Chloro-2-naphthyl)sulfonyl]-N1-methyl-N2-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinamide,-   N-Allyl-6-chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   Methyl    N-[(6-chloro-2-naphthyl)sulfonyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinate,-   Ethyl    N-[(6-chloro-2-naphthyl)sulfonyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinate,-   tert-Butyl    N-[(6-chloro-2-naphthyl)sulfonyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinate,-   N-[(6-Chloro-2-naphthyl)sulfonyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycine,-   6-Chloro-N-{(3R)-1-[(1R)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   5-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-1-benzofuran-2-sulfonamide,-   (E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide,-   5-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide,-   5-Chloro-3-methyl-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide,-   3-Cyano-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}benzenesulfonamide,-   4-Cyano-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}benzenesulfonamide,-   5-(5-Chloro-1,3,4-thiadiazol-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}thiophene-2-sulfonamide,-   5-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}thieno[2,3-b]pyridine-2-sulfonamide,-   5-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}thieno[3,2-b]pyridine-2-sulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-oxobutyl)-1-benzothiophene-2-sulfonamide,-   N2-[(6-Chloro-1-benzothien-2-yl)sulfonyl]-N2-{(3S)-1-[(l    S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinamide,-   5-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-oxobutyl)-1-benzothiophene-2-sulfonamide,-   N2-[(5-Chloro-1-benzothien-2-yl)sulfonyl]-N2-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-phenylnaphthalene-2-sulfonamide,-   6-Chloro-N-(4-fluorophenyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-pyridin-4-ylnaphthalene-2-sulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-pyridin-3-ylnaphthalene-2-sulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-thien-3-ylnaphthalene-2-sulfonamide,-   N2-[(6-Chloro-2-naphthyl)sulfonyl]-N2-((3S)-1-{(1S)-2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-1-methyl-2-oxoethyl}-2-oxopyrrolidin-3-yl)glycinamide,-   (E)-2-(3-Chloro-4-hydroxyphenyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide,-   (E)-2-(4-Chloro-3-hydroxyphenyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-morpholin-4-ylethyl)naphthalene-2-sulfonamide    formate,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-pyrrolidin-1-ylethyl)naphthalene-2-sulfonamide    formate,-   6-Chloro-N-[2-(dimethylamino)ethyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide    formate,-   N-[2-([(6-Chloro-2-naphthyl)sulfonyl]{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}amino)ethyl]acetamide,-   5-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-1H-indole-2-sulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl)-1,3-benzothiazole-2-sulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-(2-methylmorpholin-4-yl)-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   (E)-2-(5-Chlorothien-2-yl)-N-methyl-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide,    and-   (E)-2-(5-Chlorothien-2-yl)-N-methyl-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide.

More preferred compounds of the invention include:

-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-2-(2,6-dimethylmorpholin-4-yl)-1-methyl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-(3-methylmorpholin-4-yl)-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   6-Chloro-N-[(3S)-1-((1S)-1-methyl-2-{2-[(methylsulfonyl)methyl]morpholin-4-yl}-2-oxoethyl)-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide,-   6-Chloro-N-((3S)-1-{(1S)-2-[2-(methoxymethyl)morpholin-4-yl]-1-methyl-2-oxoethyl}-2-oxopyrrolidin-3-yl)naphthalene-2-sulfonamide,-   4-[(2S)-2-((3S)-3-{[(6-Chloro-2-naphthyl)sulfonyl]amino}-2-oxopyrrolidin-1-yl)propanoyl]-N-methylmorpholine-2-carboxamide,-   4-[(2S)-2-((3S)-3-{[(6-Chloro-2-naphthyl)sulfonyl]amino}-2-oxopyrrolidin-1-yl)propanoyl]-N-(2-hydroxypropyl)morpholine-2-carboxamide,-   6-Chloro-N-((3S)-1-{(1S)-1-methyl-2-oxo-2-[2-(pyrrolidin-1-ylmethyl)morpholin-4-yl]ethyl}-2-oxopyrrolidin-3-yl)naphthalene-2-sulfonamide    formate,-   6-Chloro-N-{(3S)-1-[(1S)-2-(2-{[(2-hydroxypropyl)amino]methyl}morpholin-4-yl)-1-methyl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide    formate,-   6-Chloro-N-[(3S)-1-((1S)-2-{2-[(dimethylamino)methyl]morpholin-4-yl}-1-methyl-2-oxoethyl)-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide    formate,-   6-Chloro-N-((3S)-1-{(1S)-1-methyl-2-oxo-2-[2-(piperidin-1-ylmethyl)morpholin-4-yl]ethyl}-2-oxopyrrolidin-3-yl)naphthalene-2-sulfonamide    formate,-   6-Chloro-N-((3S)-1-(1S)-2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-1-methyl-2-oxoethyl}-2-oxopyrrolidin-3-yl)naphthalene-2-sulfonamide,-   6-Chloro-N-{(3R)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   5′-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-2,2′-bithiophene-5-sulfonamide,-   (E)-2-(4-Chlorophenyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide,-   N2-{[(E)-2-(4-Chlorophenyl)ethenyl]sulfonyl}-N2-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinamide,-   N2-[(5′-Chloro-2,2′-bithien-5-yl)sulfonyl]-N2-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinamide,-   5′-Chloro-N-(cyanomethyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-2,2′-bithiophene-5-sulfonamide,-   Methyl    N-[(5′-chloro-2,2′-bithien-5-yl)sulfonyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinate,-   5′-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-oxobutyl)-2,2′-bithiophene-5-sulfonamide,-   N-[(5′-Chloro-2,2′-bithien-5-yl)sulfonyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycine,-   (E)-2-(4-Chlorophenyl)-N-(cyanomethyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide,-   (E)-2-(4-Chlorophenyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-oxobutyl)ethenesulfonamide,-   Methyl    N-{[(E)-2-(4-chlorophenyl)ethenyl]sulfonyl}-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinate,-   N-{[(E)-2-(4-Chlorophenyl)ethenyl]sulfonyl}-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycine,-   6-Chloro-N-(3-furylmethyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(pyridin-3-ylmethyl)naphthalene-2-sulfonamide    formate,-   6-Chloro-N-ethyl-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-oxobutyl)naphthalene-2-sulfonamide,-   N-2-[(6-Chloro-2-naphthyl)sulfonyl]-N-2-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinamide,-   6-Chloro-N-(2-furylmethyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(1,3-thiazol-2-ylmethyl)naphthalene-2-sulfonamide,-   N2-[(6-Chloro-2-naphthyl)sulfonyl]-N2-((3S)-1-{(1S)-2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-1-methyl-2-oxoethyl}-2-oxopyrrolidin-3-yl)glycinamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-[(2-methyl-1,3-thiazol-4-yl)methyl]naphthalene-2-sulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(pyridin-2-ylmethyl)naphthalene-2-sulfonamide    formate,-   6-Chloro-N-{(3S)-1-[(S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(pyridin-4-ylmethyl)naphthalene-2-sulfonamide    formate,-   6-Chloro-N-{(3S)-1-[(1R)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   6-Chloro-N-methyl-N-{(3S)-1-[(1R)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   6-Chloro-N-(cyanomethyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   6-Chloro-N-methyl-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   6-Chloro-N-(3,3-dimethyl-2-oxobutyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   N2-[(6-Chloro-2-naphthyl)sulfonyl]-N1-methyl-N2-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinamide,-   N-Allyl-6-chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   Methyl    N-[(6-chloro-2-naphthyl)sulfonyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinate,-   Ethyl    N-[(6-chloro-2-naphthyl)sulfonyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinate,-   tert-Butyl    N-[(6-chloro-2-naphthyl)sulfonyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinate,-   N-[(6-Chloro-2-naphthyl)sulfonyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycine,-   6-Chloro-N-{(3R)-1-[(1R)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   (E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide,-   5-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide,-   5-Chloro-3-methyl-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide,-   5-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}thieno[3,2-b]pyridine-2-sulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-oxobutyl)-1-benzothiophene-2-sulfonamide,-   N2-[(6-Chloro-1-benzothien-2-yl)sulfonyl]-N2-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinamide,-   5-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-oxobutyl)-1-benzothiophene-2-sulfonamide,-   N2-[(5-Chloro-1-benzothien-2-yl)sulfonyl]-N2-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-phenylnaphthalene-2-sulfonamide,-   6-Chloro-N-(4-fluorophenyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-pyridin-4-ylnaphthalene-2-sulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-pyridin-3-ylnaphthalene-2-sulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-thien-3-ylnaphthalene-2-sulfonamide,-   N2-[(6-Chloro-2-naphthyl)sulfonyl]-N2-((3S)-1-{(1S)-2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-1-methyl-2-oxoethyl}-2-oxopyrrolidin-3-yl)glycinamide,-   (E)-2-(4-Chloro-3-hydroxyphenyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-morpholin-4-ylethyl)naphthalene-2-sulfonamide    formate,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-pyrrolidin-1-ylethyl)naphthalene-2-sulfonamide    formate,-   6-Chloro-N-[2-(dimethylamino)ethyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide    formate,-   N-[2-([(6-Chloro-2-naphthyl)sulfonyl]{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}amino)ethyl]acetamide,-   5-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-1H-indole-2-sulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-(2-methylmorpholin-4-yl)-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,    and-   (E)-2-(5-Chlorothien-2-yl)-N-methyl-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide.

Even more preferred compounds of the invention include:

-   (E)-2-(4-Chlorophenyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   5′-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-2,2′-bithiophene-5-sulfonamide,-   N2-{[(E)-2-(4-Chlorophenyl)ethenyl]sulfonyl}-N2-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinamide,-   N2-[(5′-Chloro-2,2′-bithien-5-yl)sulfonyl]-N2-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinamide,-   5′-Chloro-N-(cyanomethyl)-N-{(3S)-1-[((1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-2,2′-bithiophene-5-sulfonamide,-   Methyl    N-[(5′-chloro-2,2′-bithien-5-yl)sulfonyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinate,-   5′-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-oxobutyl)-2,2′-bithiophene-5-sulfonamide,-   N-[(5′-Chloro-2,2′-bithien-5-yl)sulfonyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycine,-   (E)-2-(4-Chlorophenyl)-N-(cyanomethyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide,-   (E)-2-(4-Chlorophenyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-oxobutyl)ethenesulfonamide,-   Methyl    N-{[(E)-2-(4-chlorophenyl)ethenyl]sulfonyl}-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinate,-   6-Chloro-N-(3-furylmethyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(pyridin-3-ylmethyl)naphthalene-2-sulfonamide    formate,-   6-Chloro-N-ethyl-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-oxobutyl)naphthalene-2-sulfonamide,-   N-2-[(6-Chloro-2-naphthyl)sulfonyl]-N-2-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinamide,-   6-Chloro-N-(2-furylmethyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(1,3-thiazol-2-ylmethyl)naphthalene-2-sulfonamide,-   N2-[(6-Chloro-2-naphthyl)sulfonyl]-N2-((3S)-1-{(1S)-2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-1-methyl-2-oxoethyl}-2-oxopyrrolidin-3-yl)glycinamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-[(2-methyl-1,3-thiazol-4-yl)methyl]naphthalene-2-sulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(pyridin-2-ylmethyl)naphthalene-2-sulfonamide    formate,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(pyridin-4-ylmethyl)naphthalene-2-sulfonamide    formate,-   6-Chloro-N-(cyanomethyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   6-Chloro-N-methyl-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   6-Chloro-N-(3,3-dimethyl-2-oxobutyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl)naphthalene-2-sulfonamide,-   N-Allyl-6-chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   Methyl    N-[(6-chloro-2-naphthyl)sulfonyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinate,-   tert-Butyl    N-[(6-chloro-2-naphthyl)sulfonyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinate,-   N-[(6-Chloro-2-naphthyl)sulfonyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycine,-   (E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-oxobutyl)-1-benzothiophene-2-sulfonamide,-   N2-[(6-Chloro-1-benzothien-2-yl)sulfonyl]-N2-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinamide,-   N2-[(6-Chloro-2-naphthyl)sulfonyl]-N2-((3S)-1-{(1S)-2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-1-methyl-2-oxoethyl}-2-oxopyrrolidin-3-yl)glycinamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-morpholin-4-ylethyl)naphthalene-2-sulfonamide    formate,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-pyrrolidin-1-ylethyl)naphthalene-2-sulfonamide    formate,-   6-Chloro-N-[2-(dimethylamino)ethyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide    formate, and-   N-[2-([(6-Chloro-2-naphthyl)sulfonyl]{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}amino)ethyl]acetamide.

In another preferred aspect compounds of the invention also include:

-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   5′-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-2,2′-bithiophene-5-sulfonamide,-   (E)-2-(4-Chlorophenyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide,-   5′-Chloro-N-(cyanomethyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-2,2′-bithiophene-5-sulfonamide,-   Methyl    N-[(5′-chloro-2,2′-bithien-5-yl)sulfonyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinate,-   5′-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-oxobutyl)-2,2′-bithiophene-5-sulfonamide,-   6-Chloro-N-(3-furylmethyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(pyridin-3-ylmethyl)naphthalene-2-sulfonamide    formate,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-oxobutyl)naphthalene-2-sulfonamide,-   N-2-[(6-Chloro-2-naphthyl)sulfonyl]-N-2-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinamide,-   6-Chloro-N-(2-furylmethyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(1,3-thiazol-2-ylmethyl)naphthalene-2-sulfonamide,-   6-Chloro-N-(cyanomethyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   6-Chloro-N-methyl-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   N-Allyl-6-chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,-   Methyl    N-[(6-chloro-2-naphthyl)sulfonyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinate,    and-   N-[(6-Chloro-2-naphthyl)sulfonyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycine.

The compounds of formula (I) or (Ia) are Factor Xa inhibitors and assuch are useful in the treatment of clinical conditions susceptible toamelioration by administration of a Factor Xa inhibitor. Such conditionsinclude acute vascular diseases such as coronary thrombosis (for examplemyocardial infarction and unstable angina), thromboembolism, acutevessel closure associated with thrombolylic therapy and percutaneoustransluminal coronary angioplasty (PTCA), transient ischemic attacks,pulmonary embolism, deep vein thrombosis, peripheral arterial occlusion,prevention of vessel luminal narrowing (restenosis), and the preventionof thromboembolic events associated with atrial fibrillation, e.g.stroke; in oedema and PAF mediated inflammatory diseases such as adultrespiratory shock syndrome, septic shock and reperfusion damage; thetreatment of pulmonary fibrosis; the treatment of tumour metastasis;neurogenerative disease such as Parkinson's and Alzheimer's diseases;viral infection; Kasabach Merritt Syndrome; Haemolylic uremic syndrome;arthritis; osteoporosis; as anti-coagulants for extracorporeal blood infor example, dialysis; blood filtration, bypass, and blood productstorage; and in the coating of invasive devices such as prostheses,artificial valves and catheters in reducing the risk of thrombusformation.

Accordingly, one aspect of present invention provides a compound offormula (I) or (Ia) or a physiologically acceptable salt or solvatethereof for use in medical therapy, particularly for use in theamelioration of a clinical condition in a mammal, including a human, forwhich a Factor Xa inhibitor is indicated.

In another aspect, the invention provides a method for the treatmentand/or prophylaxis of a mammal, including a human, suffering from acondition susceptible to amelioration by a Factor Xa inhibitor whichmethod comprises administering to the subject an effective amount of acompound of formula (I) or (Ia) or a pharmaceutically acceptable salt orsolvate thereof.

In another aspect, the present invention provides the use of a compoundof formula (I) or (Ia) or a pharmaceutically acceptable salt or solvatethereof, for the manufacture of a medicament for the treatment and/orprophylaxis of a condition susceptible to amelioration by a Factor Xainhibitor.

Preferably, the condition susceptible to amelioration by a Factor Xainhibitor is selected from coronary thrombosis (for example myocardialinfarction and unstable angina), pulmonary embolism, deep veinthrombosis and the prevention of thromboembolic events associated withatrial fibrillation, e.g. stroke;

It will be appreciated that reference to treatment includes acutetreatment or prophylaxis as well as the alleviation of establishedsymptoms.

While it is possible that, for use in therapy, a compound of the presentinvention may be administered as the raw chemical, it is preferable topresent the active ingredient as a pharmaceutical formulation.

In a further aspect, the invention provides a pharmaceutical compositioncomprising at least one compound of formula (I) or (Ia) or apharmaceutically acceptable salt or solvate thereof in association witha pharmaceutically acceptable carrier and/or excipient. The carrierand/or excipient must be “acceptable” in the sense of being compatiblewith the other ingredients of the formulation and not deletrious to thereceipient thereof.

Accordingly, the present invention further provides a pharmaceuticalformulation comprising at least one compound of formula (I) or (Ia) or apharmaceutically acceptable salt or solvate thereof, thereof inassociation with a pharmaceutically acceptable carrier and/or excipient.The carrier and/or excipient must be “acceptable” in the sense of beingcompatible with the other ingredients of the formulation and notdeletrious to the receipient thereof.

In another aspect, the invention provides a pharmaceutical compositioncomprising, as active ingredient, at least one compound of formula (I)or (Ia) or a pharmaceutically acceptable salt or solvate thereof inassociation with a pharmaceutically acceptable carrier and/or excipientfor use in therapy, and in particular in the treatment of human oranimal subjects suffering from a condition susceptible to ameliorationby a Factor Xa inhibitor.

There is further provided by the present invention a process ofpreparing a pharmaceutical composition, which process comprises mixingat least one compound of formula (I) or (Ia) or a pharmaceuticallyacceptable salt or solvate thereof, together with a pharmaceuticallyacceptable carrier and/or excipient.

The compounds for use according to the present invention may beformulated for oral, buccal, parenteral, topical, rectal or transdermaladministration or in a form suitable for administration by inhalation orinsufflation (either through the mouth or the nose).

For oral administration, the pharmaceutical compositions may take theform of, for example, tablets or capsules prepared by conventional meanswith pharmaceutically acceptable excipients such as binding agents (e.g.pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropylmethylcellulose); fillers (e.g. lactose, microcrystalline cellulose orcalcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talcor silica); disintegrants (e.g. potato starch or sodium starchglycollate); or wetting agents (e.g. sodium lauryl sulphate). Thetablets may be coated by methods well known in the art. Liquidpreparations for oral administration may take the form of, for example,solutions, syrups or suspensions or they may be presented as a dryproduct for constitution with water or other suitable vehicles beforeuse. Such liquid preparations may be prepared by conventional means withpharmaceutically acceptable additives such as suspending agents (e.g.sorbitol syrup, cellulose derivatives or hydrogenated edible fats);emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g.almond oil, oily esters, ethyl alcohol or fractionated vegetable oils);and preservatives (e.g. methyl or propyl-p-hydroxybenzoates or sorbicacid). The preparations may also contain buffer salts, flavouring,colouring and sweetening agents as appropriate.

Preparations for oral administration may be suitably formulated to givecontrolled release of the active compound.

For buccal administration the compositions may take the form of tabletsor lozenges formulated in a conventional manner.

The compounds according to the present invention may be formulated forparenteral administration by injection, e.g. by bolus injection orcontinuous infusion. Formulations for injection may be presented in unitdosage form, e.g. in ampoules or in multi-dose containers, with an addedpreservative. The compositions may take such forms as suspensions,solutions or emulsions in oily or aqueous vehicles, and may containformulatory agents such as suspending, stabilising and/or dispersingagents. Alternatively, the active ingredient may be in powder form forconstitution with a suitable vehicle, e.g. sterile pyrogen-free water,before use.

The compounds according to the present invention may be formulated fortopical administration by insufflation and inhalation. Examples of typesof preparation for topical administration include sprays and aerosolsfor use in an inhaler or insufflator.

Powders for external application may be formed with the aid of anysuitable powder base, for example, lactose, talc or starch. Spraycompositions may be formulated as aqueous solutions or suspensions or asaerosols delivered from pressurised packs, such as metered doseinhalers, with the use of a suitable propellant.

The compounds according to the present invention may also be formulatedin rectal compositions such as suppositories or retention enemas, e.g.containing conventional suppository bases such as cocoa butter or otherglycerides.

In addition to the formulations described previously, the compounds mayalso be formulated as a depot preparation. Such long acting formulationsmay be administered by implantation (for example subcutaneously,transcutaneously or intramuscularly) or by intramuscular injection.Thus, for example, the compounds according to the present invention maybe formulated with suitable polymeric or hydrophobic materials (forexample as an emulsion in an acceptable oil) or ion exchange resins oras sparingly soluble derivatives, for example, as a sparingly solublesalt.

A proposed dose of the compounds according to the present invention foradministration to a human (of approximately 70 kg body weight) is 0.1 mgto 1 g, preferably to 1 mg to 500 mg of the active ingredient per unitdose, expressed as the weight of free base. The unit dose may beadministered, for example, I to 4 times per day. The dose will depend onthe route of administration. It will be appreciated that it may benecessary to make routine variations to the dosage depending on the ageand weight of the patient as well as the severity of the condition to betreated. The dosage will also depend on the route of administration. Theprecise dose and route of administration will ultimately be at thediscretion of the attendant physician or veterinarian.

The compounds of formula (I) or (Ia) may also be used in combinationwith other therapeutic agents. The invention thus provides, in a furtheraspect, a combination comprising a compound of formula (I) or (Ia) or apharmaceutically acceptable salt or solvate thereof together with afurther therapeutic agent.

When a compound of formula (I) or (Ia) or a pharmaceutically acceptablesalt or solvate thereof is used in combination with a second therapeuticagent active against the same disease state the dose of each compoundmay differ from that when the compound is used alone. The compounds ofthe present invention may be used in combination with otherantithrombotic drugs such as thrombin inhibitors, thromboxane receptorantagonists, prostacyclin mimetics, phosphodiesterase inhibitors,fibrinogen antagonists, thrombolylic drugs such as tissue plaminogenactivator and streptokinase, non-steroidal anti-inflammatory drugs suchas aspirin, and the like.

The combinations referred to above may conveniently be presented for usein the form of a pharmaceutical formulation and thus pharmaceuticalformulations comprising a combination as defined above together with apharmaceutically acceptable carrier or excipient comprise a furtheraspect of the invention. The individual components of such combinationsmay be administered either sequentially or simultaneously in separate orcombined pharmaceutical formulations by any convenient route.

When administration is sequential, either the Factor Xa inhibitor or thesecond therapeutic agent may be administered first. When administrationis simultaneous, the combination may be administered either in the sameor different pharmaceutical composition.

When combined in the same formulation it will be appreciated that thetwo compounds must be stable and compatible with each other and theother components of the formulation. When formulated separately they maybe provided in any convenient formulation, conveniently in such manneras are known for such compounds in the art.

When a compound of formula (I) or (Ia) or a pharmaceutically acceptablesalt or solvate thereof is used in combination with a second therapeuticagent active against the same disease state the dose of each compoundmay differ from that when the compound is used alone. Appropriate doseswill be readily appreciated by those skilled in the art. It will beappreciated that the amount of a compound of the invention required foruse in treatment will vary with the nature of the condition beingtreated and the age and the condition of the patient and will beultimately at the discretion of the attendant physician or veterinarian.

The compounds of formula (I) or (Ia) and physiologically acceptablesalts or solvates thereof may be prepared by the processes describedhereinafter, said processes constituting a further aspect of theinvention. In the following description, the groups are as defined abovefor compounds of formula (I) or (Ia) unless otherwise stated.

According to a further aspect of the present invention, there isprovided a process (A) for preparing a compound of formula (I) or (Ia),which process comprises reacting a compound of formula (II) with acompound of formula (III).

Suitably, the reaction may be carried out in the presence of a couplingagent, for example 1-[3-(dimethylamino)propyl]-3-ethyl carbodiimidehydrochloride, HOBt (1-hydroxybenzotriazole), a base, e.g. Et₃N(triethylamine), and an organic solvent, e.g. DCM (dichloromethane),suitably at room temperature.

It will be appreciated by persons skilled in the art that compounds offormula (I) or (Ia) may be prepared by interconversion, utilising othercompounds of formula (I) or (Ia) which are optionally protected bystandard protecting groups, as precursors. For instance, compounds offormula (I) or (Ia) where B represents —C₁₋₃alkylNH₂, may be convertedinto compounds of formula (I) or (Ia) possessing alternativesubstituents on the heterocyclic ring, e.g. —C₁₋₃alkylNR^(b)R^(c), bymethods well known in the art (see for example March, J., AdvancedOrganic Chemistry, John Wiley & Sons).

Compounds of formula (II) may be prepared from compounds of formula(IV):

wherein P¹ is a suitable carboxylic acid protecting group, e.g. t-Butyl,by removal of the protecting group under standard conditions. Forexample, when P¹ represents t-Butyl, removal of the protecting group maybe effected under acidic conditions, using for example TFA(trifluoroacetic acid) in a solvent such as DCM.

A compound of formula (IV) may be prepared by reacting a compound offormula (V) with a compound of formula (VI) where P¹ is as describedabove:

Suitably, where X is a leaving group such as a halogen atom, e.g.bromine, the reaction is carried out in the presence of a base, e.g.LiHMDS (lithium hexamethyldisilylamide), potassium carbonate or sodiumcarbonate. Preferably, the reaction is effected in a suitable organicsolvent, e.g. THF, DMF, at a temperature from −78° C. to +50° C.,preferably −78° C. to +20° C.

Alternatively, where X is hydroxy, the coupling reaction is carried outusing standard reagents such as DIAD (diisopropyl azodicarboxylate) andn-Bu₃P (tri n-Butyl phosphine) in a solvent such as tetrahydrofuran,suitably at room temperature.

A compound of formula (V) may be prepared by reacting a compound offormula (VII) with a compound of formula (VIII):

wherein T is a reactive group, such as a halide, preferably chloride,and P¹ is as described above. The reaction is conveniently carried outin the presence of a base, e.g. pyridine, and in a suitable solvent,e.g. DCM, suitably at room temperature.

A compound of formula (VII) may be prepared from a compound of formula(IX)

where P¹ is as described above and P² represents a suitable amineprotecting group, e.g. Cbz (benzyloxycarbonyl), by removal of theprotecting group under standard conditions. For example, the protectinggroup may be removed by reaction with hydrogen in the presence of ametal catalyst, e.g. palladium/charcoal at atmospheric pressure.Suitably, the reaction is carried out in an alcoholic solvent, e.g.ethanol, suitably at room temperature.

A compound of formula (IX) may be prepared from a compound of formula(X)

by cyclisation, wherein P¹ and P² are as described above and Lrepresents a leaving group, e.g. SMeRX. The ring closure may beperformed by treatment with Dowex 2×8 400 mesh OH⁻ resin in a suitablesolvent, e.g. MeCN (acetonitrile). Alternatively, the ring closure maybe performed by treatment with potassium carbonate in a suitablesolvent, e.g. MeCN. Generally R will represent alkyl or aralkyl and Xwill represent halide, especially iodide or sulphate.

Alternatively, a compound of formula (IX) may be prepared from acompound of formula (Xb):

where P¹ and P³ are protecting groups, by reaction with LiOH in asuitable solvent e.g. THF followed by reaction with DPPA(diphenylphosphoryl azide), a base e.g. Et₃N (triethylamine) in asuitable solvent e.g. DMF, suitably at room temperature to 70° C.

A compound of formula (Xb) may be prepared by reacting a compound offormula (Xb-1) with a compound of formula (Xb-2)

where L¹ is a leaving group e.g. bromine, in the presence of a base e.g.Et₃N in a suitable solvent e.g. MeCN.

A compound of formula (X) in which L represents SMeRX may be formed froma compound of formula (XI)

by treatment with RX, where P¹ and P² are as described above and RX is acompound (e.g. MeI, benzyl iodide or Me₂SO₄) capable of convertingsulphur in the SMe moiety to a sulphonium salt, in a suitable solvent,e.g. propanone or acetonitrile.

A compound of formula (XI) may be prepared by reacting a compound offormula (XII) with a compound of formula (XIII):

Suitably, the reaction may be carried out in the presence of a couplingagent, for example 1-[3-(dimethylamino)propyl]-3-ethyl carbodiimidehydrochloride, HOBt, a base, e.g. Et₃N, and an organic solvent, e.g.DCM, suitably at room temperature.

There is provided a further process (B) for preparing compounds offormula (IV) from compounds of formula (VII). According to process (B),a compound of formula (IV) may be prepared by reductive amination of acompound of formula (VII) with R^(1a)CHO (where R^(1a) is R¹ without aCH₂ linker directly attached to the N) using a suitable selectivereducing agent to produce a compound of formula (XIV), followed byreaction with a compound of formula (VIII) in the presence of a base,e.g. pyridine, and in a solvent, e.g. DCM, suitably at room temperature.

The reductive amination is conveniently carried out by treatment withsodium triacetoxyborohydride in the presence of an acid such as aceticacid, in a solvent such as DCM, suitably at room temperature.

Compounds of formulae (III), (VI), (VIII), (Xb-1), (Xb-2), (X), (XI),(XII) and (XIII) are known compounds and/or can be prepared by processeswell known in the art.

The various general methods described above may be useful for theintroduction of the desired groups at any stage in the stepwiseformation of the required compound, and it will be appreciated thatthese general methods can be combined in different ways in suchmulti-stage processes. The sequence of the reactions in multi-stageprocesses should of course be chosen so that the reaction conditionsused do not affect groups in the molecule which are desired in the finalproduct. For example, those skilled in the art will appreciate that,with the use of appropriate protecting groups, the coupling to any ofgroups —R¹, —SO₂A or formula (III) can be the final step in thepreparation of a compound of formula (I) or (Ia). Hence, in anotheraspect of the invention, the final step in the preparation of a compoundof formula (I) or (Ia) may comprise the coupling to group —R¹ byreacting a compound of formula (XV) with a compound of formula (VI):

Suitably, where X is a leaving group such as a halogen atom, e.g.bromine, the reaction is carried out in the presence of a base, e.g.LiHMDS (lithium hexamethyldisilylamide), potassium carbonate or sodiumcarbonate. Preferably, the reaction is effected in a suitable organicsolvent, e.g. THF, DMF, at a temperature from −78° C. to +50 C.,preferably −78° C. to +20 C.

In a further aspect of the present invention, the final step in thepreparation of a compound of formula (I) or (Ia) may comprise thecoupling to group —SO₂A by reacting a compound of formula (XVI) with acompound of formula (VIII):

The reaction is conveniently carded out in the presence of a base, e.g.pyridine, and in a suitable solvent, e.g. DCM, suitably at roomtemperature.

In a further aspect of the present invention, a compound of formula (I)where R¹ is an aryl or heteroaryl group may be prepared from a compoundof formula (XV) by reaction with a compound of formula (XVII):R¹—C¹  (XVII)where C¹ is a suitable coupling group e.g. boronate [B(OH)₂] under metalcatalysis, for example, with a copper salt such as copper(II) acetate,in the presence of an organic solvent e.g. DCM and a base, e.g. pyridineand optionally in the presence of molecular sieves.

In a further aspect of the present invention, a compound of formula (I)where A is —SO₂—CH═CH-aryl, SO₂—CH═CH-heteroaryl, SO₂—C(CH₃)═CH-aryl orSO₂—C(CH₃)═CH-heteroaryl may be prepared from a compound of formula(XVI) where R¹ is hydrogen, by reaction with a compound of formula(XVIII), or alternatively with a compound of formula (XIX):T¹-SO₂—C(R)═CH₂  (XVIII)T¹-SO₂—C(R)—CH₂—T²  (XIX)where T¹ and T² are independently reactive groups, such as a halide,preferably chloride, in the presence of a base e.g.N,N-diisopropylethylamine and a suitable solvent e.g. MeCN, suitably atroom temperature, to provide a compound of formula (XV) where A isC(R)═CH₂, followed by reaction with a compound of formula (XX):L-R^(h)  (XX)

Where R^(h) is aryl or heteroaryl and L is a leaving group, e.g.bromine, in the presence of a base e.g. N,N-diisopropylethylamine, and asuitable solvent e.g. dioxane and a suitable transition metal catalyste.g. di(palladium)tris(dibenzylideneacetone) and a suitable ligand e.g.2-(di-t-butylphosphino)biphenyl under an inert atmosphere e.g. nitrogen,at a temperature 20-100° C. preferably 40° C.

In a further aspect of the present invention, a compound of formula (I)where A is a biaryl group may be prepared from a compound of formula(XVI) where R¹ is hydrogen and the amino group is optionally protected,for example, as a solid supported derivative derived from reductiveamination under standard conditions, by reaction with a compound offormula of formula (XXI):

wherein T is a reactive group, such as a halide, preferably chloride,and M¹ is an aryl or heteroaryl group with a suitable coupling groupe.g. halogen, preferably bromide or iodide, in the presence of asuitable solvent e.g. DMF and a suitable base, e.g.N,N-diisopropylethylamine, followed by reaction with a compound offormula (XXII):M²-C²  (XXII)wherein M² is an aryl or heteroaryl group and C² is a suitable couplinggroup e.g. boronate [B(OH)₂], in the presence of a metal catalyst e.g.tetrakis(triphenylphosphine)palladium(0), a base e.g. sodium carbonate,a suitable solvent e.g. THF and optionally in the presence of acosolvent e.g. H₂O, followed by removal of any protecting groups understandard conditions, e.g. under standard conditions.

Those skilled in the art will appreciate that in the preparation of thecompound of formula (I) or (Ia) or a solvate thereof it may be necessaryand/or desirable to protect one or more sensitive groups in the moleculeto prevent undesirable side reactions. Suitable protecting groups foruse according to the present invention are well known to those skilledin the art and may be used in a conventional manner. See, for example,“Protective groups in organic synthesis” by T. W. Greene and P. G. M.Wuts (John Wiley & sons 1991) or “Protecting Groups” by P. J. Kocienski(Georg Thieme Verlag 1994). Examples of suitable amino protecting groupsinclude acyl type protecting groups (e.g. formyl, trifluoroacetyl,acetyl), aromatic urethane type protecting groups (e.g.benzyloxycarbonyl (Cbz) and substituted Cbz), aliphatic urethaneprotecting groups (e.g. 9-fluorenylmethoxycarbonyl (Fmoc),t-butyloxycarbonyl (Boc), isopropyloxycarbonyl, cyclohexyloxycarbonyl)and alkyl type protecting groups (e.g. benzyl, trityl, chlorotrityl).Examples of suitable oxygen protecting groups may include for examplealky silyl groups, such as trimethylsilyl or tert-butyldimethylsilyl;alkyl ethers such as tetrahydropyranyl or tert-butyl; or esters such asacetate.

Various intermediate compounds used in the above-mentioned process,including but not limited to certain compounds of formulae formulae(II), (IV), (V), (VII), (IX), (XIV), (XV) and (XVI) are novel andaccordingly constitute a further aspect of the present invention.

The present invention will now be further illustrated by theaccompanying examples which should not be construed as limiting thescope of the invention in any way.

EXAMPLES Abbreviations

-   Boc t-Butyloxycarbonyl-   Cbz Benzyloxycarbonyl-   THF Tetrahydrofuran-   DCM Dichloromethane-   DMF N,N-Dimethylformamide-   HOBT 1-Hydroxybenzotriazole-   br broad-   m multiplet-   q quartet-   s singlet-   t triplet-   d doublet

Intermediate 1 tert-ButylN-[(benzyloxy)carbonyl]-L-methionyl-L-alaninate

Z-Protected L-methionine (10 g) was dissolved in DMF (200 ml) and1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (8.13 g)was added followed by HOBT (5.72 g) and triethylamine (19.7 ml). Themixture was stirred for 1 h then L-alanine tert-butyl ester (7.7 g) wasadded and stirring continued for 18h. The mixture was concentrated underreduced pressure and partitioned between diethyl ether and water. Theseparated organic phase was washed with hydrochloric acid (1M),saturated sodium bicarbonate solution and brine, dried (over magnesiumsulphate) and concentrated under reduced pressure to give the titlecompound (11.9 g) as an orange oil which crystallised on standing.

Mass spectrum: Found: MH⁺ 411

Intermediate 2 tert-ButylN-[(benzyloxy)carbonyl]-D-methionyl-L-alaninate

Using Z-protected D-methionine, L-alanine tert-butyl ester, and theprocedure described for Intermediate 1, the title compound was prepared.

Mass spectrum: Found: MH⁺ 411

Intermediate 3 tert-ButylN-[(benzyloxy)carbonyl]-D-methionyl-D-alaninate

Using Z-protected D-methionine, D-alanine tert-butyl ester and theprocedure described for Intermediate 1, the title compound was prepared.

Mass spectrum: Found: MH⁺ 411

Intermediate 4 tert-ButylN-[(benzyloxy)carbonyl]-L-methionyl-D-alaninate

Using Z-protected L-methionine, D-alanine tert-butyl ester and theprocedure described for Intermediate 1, the title compound was prepared.

Mass spectrum: Found: MH⁺ 411

Intermediate 5 tert-Butyl(2S)-2-((3S)-3-{[(benzyloxy)carbonyl]amino}-2-oxopyrrolidin-1-yl)propanoate

A solution of Intermediate 1 (11.9 g) in acetone (75 ml) was treatedwith methyl iodide (18 ml) and stirred at room temperature for 72 h. Thereaction mixture was then concentrated under reduced pressure to give anorange solid that was dissolved in acetonitrile (200 ml). Dowex (OH⁻form) resin (19.42 g) was added and the mixture stirred for 18 h at roomtemperature. The mixture was filtered and the resin washed with ethylacetate. The filtrate was concentrated under reduced pressure to afforda yellow oil which was purified by Biotage™ chromatography (eluting withcyclohexane:ethyl acetate 3:2) to give the title compound (2.92 g) as acolourless oil.

Mass spectrum: Found: MH⁺ 363

Intermediate 6 tert-Butyl(2S)-2-((3R)-3-{[(benzyloxy)carbonyl]amino}-2-oxopyrrolidin-1-yl)propanoate

Using Intermediate 2 and the procedure described for Intermediate 5, thetitle compound was prepared.

Mass spectrum: Found: MH⁺ 363

Intermediate 7 tert-Butyl(2R)-2-((3R)-3-{[(benzyloxy)carbonyl]amino}-2-oxopyrrolidin-1-yl)propanoate

Using Intermediate 3 and the procedure described for Intermediate 5, thetitle compound was prepared.

Mass spectrum: Found: MH⁺ 363

Intermediate 8 tert-Butyl(2R)-2-((3S)-3-{[(benzyloxy)carbonyl]amino}-2-oxopyrrolidin-1-yl)propanoate

Using Intermediate 4 and the procedure described for Intermediate 5, thetitle compound was prepared.

Mass spectrum: Found: MH⁺ 363

Intermediate 9 tert-Butyl(2S)-2-[(3S)-3-amino-2-oxopyrrolidin-1-yl]propanoate

A mixture of tert-butyl(2S)-2-((3S)-3-{[(benzyloxy)carbonyl]amino}-2-oxopyrrolidin-1-yl)propanoate(2.82 g), 10% palladium on carbon (0.3 g) and ethanol (150 ml) wasstirred under an atmosphere of hydrogen for 18 h. The reaction mixturewas filtered through Harbolite™ and the filtrate was concentrated underreduced pressure to give the title compound (1.8 g) as a pale yellowoil.

¹H NMR (D₄MeOH): δ 4.56 (1H, q), 3.57 (1H, dd), 3.49-3.35 (2H, 2×m),2.48-2.39 (1H, m), 1.88-1.77 (1H, m), 1.47 (9H, s), 1.40 (3H, d) ppm.

Intermediate 10 tert-Butyl(2S)-2-[(3R)-3-amino-2-oxopyrrolidin-1-yl]propanoate

Using Intermediate 6 and the procedure described for Intermediate 9, thetitle compound was prepared.

¹H NMR (D₄MeOH): δ 4.60 (1H, q), 3.58 (1H, dd), 3.46 (1H, dt), 3.41-3.33(1H, m), 2.48-2.40 (1H, m), 1.82-1.70 (1H, m), 1.45 (9H, s), 1.40 (3H,d) ppm.

Intermediate 11 tert-Butyl(2R)-2-[(3R)-3-amino-2-oxopyrrolidin-1-yl]propanoate

Using Intermediate 7 and the procedure described for Intermediate 9, thetitle compound was prepared.

¹H NMR (D₄MeOH): δ 4.58 (1H, q), 3.75 (1H, dd), 3.55-3.41 (2H, 2×m),2.50 (1H, m), 1.90 (1H, m), 1.49 (9H, s), 1.42 (3H, d) ppm.

Intermediate 12 tert-Butyl(2R)-2-[(3S)-3-amino-2-oxopyrrolidin-1-yl]propanoate

Using Intermediate 8 and the procedure described for Intermediate 9, thetitle compound was prepared.

¹H NMR (D₄MeOH): δ 4.68 (1H, q), 3.78 (1H, t), 3.56-3.40 (2H, 2×m), 2.52(1H, m), 1.89 (1H, m), 1.48 (9H, s), 1.42 (3H, d) ppm.

Intermediate 13(2S)-2-((3S)-3-{[(Benzyloxy)carbonyl]amino}-2-oxopyrrolidin-1-yl)propanoicacid

tert-Butyl(2S)-2-((3S)-3-{[(benzyloxy)carbonyl]amino}-2-oxopyrrolidin-1-yl)propanoate(0.5 g) was dissolved in DCM (7 ml), and trifluoroacetic acid (4.7 ml)was added. The mixture was stirred at room temperature for 4 h and thenconcentrated under reduced pressure to give the title compound (0.423 g)as a colourless oil, which after azeotroping with toluene, crystallised.

Mass spectrum: Found: MH⁺ 307

Intermediate 14 tert-Butyl(2S)-2-((3S)-3-{[(6-chloro-2-naphthyl)sulfonyl]amino}-2-oxopyrrolidin-1-yl)propanoate

A solution of tert-butyl(2S)-2-[(3S)-3-amino-2-oxopyrrolidin-1-yl]propanoate (1.8 g) in DCM (75ml) was treated with 6-chloronaphthylsulphonyl chloride¹ (2.28 g) andpyridine (0.705 ml) and stirred at room temperature for 72 h. Themixture was washed with water and concentrated under reduced pressure toyield an oil which was purified by Biotage™ chromatography (eluting withcyclohexane:ethyl acetate 3:1) to give the title compound (2.31 g), as awhite solid.

Mass spectrum: Found: MH⁺ 453

Intermediate 15 tert-Butyl(2S)-2-((3R)-3-{[(6-chloro-2-naphthyl)sulfonyl]amino}-2-oxopyrrolidin-1-yl)propanoate

Using Intermediate 10 and the procedure described for Intermediate 14,the title compound was prepared.

¹H NMR (CDCl₃): δ 8.45 (1H, br.s), 7.96-7.83 (4H, m), 7.56 (1H, dd),5.41 (1H, br.s), 4.66 (1H, q), 3.73 (1H, dt), 3.42-3.34 (2H, m), 2.62(1H, m), 2.01 (1H, m), 1.381.32 (12H, s+d) ppm.

Intermediate 16 tert-Butyl(2R)-2-((3R)-3-{[(6-chloro-2-naphthyl)sulfonyl]amino}-2-oxopyrrolidin-1-yl)propanoate

Using Intermediate 11 and the procedure described for Intermediate 14,the title compound was prepared.

Mass spectrum: Found: MH⁺ 453

Intermediate 17(2S)-2-((3S)-3-{[(6-Chloro-2-naphthyl)sulfonyl]amino}-2-oxopyrrolidin-1-yl)propanoicacid

tert-Butyl(2S)-2-((3S)-3-{[(6-chloro-2-naphthyl)sulfonyl]amino}-2-oxopyrrolidin-1-yl)propanoate(0.643 g) was dissolved in DCM (19 ml), and trifluoroacetic acid (19 ml)was added. The mixture was stirred at room temperature for 2.5 h andthen concentrated under reduced pressure. Anhydrous DCM (4 ml) was addedand the solution concentrated under reduced pressure. Repetitiveaddition of DCM and concentration under reduced pressure provided thetitle compound (0.56 g) as a white foam.

Mass spectrum: Found: MH⁺ 397

Intermediate 18(2S)-2-((3R)-3-{[(6-Chloro-2-naphthyl)sulfonyl]amino}-2-oxopyrrolidin1-yl)propanoic acid

Using Intermediate 15 and the procedure described for Intermediate 17,the title compound was prepared.

Mass spectrum: Found: MH⁺ 397

Intermediate 19(2R)-2-((3R)-3-{[(6-Chloro-2-naphthyl)sulfonyl]amino}-2-oxopyrrolidin-1-yl)propanoicacid

Using Intermediate 16 and the procedure described for Intermediate 17,the title compound was prepared.

Mass spectrum: Found: MH⁺ 397

Intermediate 20 tert-Butyl(2R)-2-(3-azido-2-oxopyrrolidin-1-yl)propanoate

To a solution of D-alanine tert-butylester (1.28 g) andN,N-diisopropylethylamine (1.22 ml) in acetonitrile (15 ml), was added asolution of ethyl 2-azido-4-bromobutanoate (1 g) and sodium iodide (0.02g) in acetonitrile (5 ml). The mixture was heated at 60° C. for 60 h andthen concentrated under reduced pressure to give a brown oil. This oilwas partitioned between DCM and water. The separated organic layer waswashed further with water and dried (over magnesium sulphate), andconcentrated under reduced pressure. The residual brown oil was purifiedusing Biotage™ chromatography (silica, eluting with cyclohexane:ethylacetate 3:1) to give the title compound (0.204 g) as a mixture of twodiastereoisomers.

T.l.c. (cyclohexane:ethyl acetate, 2:1) R_(f) 0.20

Intermediates 16 and 21 tert-Butyl(2R)-2-((3R)-3-{[(6-chloro-2-naphthyl)sulfonyl]amino}-2-oxopyrrolidin-1-yl)propanoate(1) tert-Butyl(2R)-2-((3S)-3-{[(6-chloro-2-naphthyl)sulfonyl]amino}-2-oxopyrrolidin-1-yl)propanoate(2)

A mixture of tert-butyl (2R)-2-(3-azido-2-oxopyrrolidin-1-yl)propanoate(0.204 g), 10% palladium on carbon (0.02 g) and ethanol (10 ml) wasstirred under an atmosphere of hydrogen for 5 h. The reaction mixturewas filtered through Harbolite™ and the filtrate was concentrated underreduced pressure to give a yellow oil. The oil (0.150 g) in DCM (10 ml)was treated with 6-chloronaphthylsulphonyl chloride¹ (0.188 g) andpyridine (0.058 ml) and stirred at room temperature for 72 h. Themixture was washed with water and concentrated under reduced pressure toyield an oil which was purified by Biotage™ chromatography (eluting withcyclohexane:ethyl acetate 2:1) to give the title compounds [(1)—0.067 gand (2)—0.060 g], both as white solids.

(1) Mass spectrum: Found: MH⁺ 453

(2) Mass spectrum: Found: MH⁺ 453

Intermediate 22 tert-Butyl(2S)-2-{(3S)-3-[[(6-chloro-2-naphthyl)sulfonyl](2-oxobutyl)amino]-2-oxopyrrolidin-1-yl}propanoate

A solution of tert-butyl(2S)-2-((3S)-3-{[(6-chloro-2-naphthyl)sulfonyl]amino}-2-oxopyrrolidin-1-yl)propanoate(0.07 g) in THF (2 ml) was cooled to −78° C. under nitrogen, and treatedwith lithium bis(trimethylsilyl)amide (1.0M solution in THF; 0.186 ml),followed by 1-bromo-2-butanone (0.08 ml). The resultant solution wasallowed to reach room temperature and stirred for a further 72 h.Methanol (1 ml) was added and the resultant solution concentrated underreduced pressure. The residue was purified using SPE (silica, elutingwith cyclohexane:ethyl acetate 10:1, 5:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:5,ethyl acetate and methanol:ethyl acetate 1:9) to give the title compound(0.07 g) as a gum.

Mass spectrum: Found: MH⁺ 523

Similarly prepared using other commercially available alkyl halides,was:

Intermediate 23 tert-Butyl(2S)-2-((3S)-3-{(2-amino-2-oxoethyl)[(6-chloro-2-naphthyl)sulfonyl]amino}-2-oxopyrrolidin-1-yl)propanoate

Mass spectrum: Found: MH⁺ 510

Intermediate 24 tert-Butyl(2R)-2-{((3S)-3-[[(6-chloro-2-naphthyl)sulfonyl](methyl)amino]-2-oxopyrrolidin-1-yl}poropanoate

The title compound was prepared using Intermediate 21 and methyltosylate, and the synthetic procedure described for Intermediate 22.

Mass spectrum: Found: MH⁺ 467

Intermediate 25(2S)-2-[(3S)-3-[[(6-Chloro-2-naphthyl)sulfonyl](2-oxobutyl)amino]-2-oxopyrrolidin-1yl}propanoicacid

tert-Butyl(2S)-2-{(3S)-3-[[(6-chloro-2-naphthyl)sulfonyl](2-oxobutyl)amino]-2-oxopyrrolidin-1-yl}propanoate(0.07 g) was dissolved in DCM (2 ml), and trifluoroacetic acid (2 ml)was added. The mixture was stirred at room temperature for 1.5 h andthen partitioned between water and DCM. The organic layer was separated,dried (over magnesium sulphate) and concentrated under reduced pressureto give the title compound (0.063 g) as an orange gum.

Mass spectrum: Found: MH⁺ 467

Intermediate 26(2S)-2-((3S)-3-[(2-Amino-2-oxoethyl)[(6-chloro-2-naphthyl)sulfonyl]amino}-2-oxopyrrolidin-1-yl)propanoicacid

Using Intermediate 23 and similar chemistry to that described forIntermediate 25, the title compound was prepared.

Mass spectrum: Found: MH⁺ 454

Intermediate 27(2R)-2-{(3S)-3-[[(6-Chloro-2-naphthyl)sulfonyl](methyl)amino]-2-oxopyrrolidin-1-yl}propanoicacid

Using Intermediate 24 and similar chemistry to that described forIntermediate 25, the title compound was prepared.

Mass spectrum: Found: MH⁺ 411

Intermediate 28(2R)-2-((3S)-3-{[(6-Chloro-2-nahthyl)sulfonyl]amino}-2-oxopyrrolidin-1-yl)propanoicacid

Using Intermediate 21 and the procedure described for Intermediate 13,the title compound was similarly prepared.

Mass spectrum: Found: MH⁺ 397

Intermediate 29 tert-Butyl(2S)-2-{(3S)-3-[[(6-chloro-2-naphthyl)sulfonyl](2-furylmethyl)amino]-2-oxopyrrolidin-1-yl}propanoate

A solution of tert-butyl(2S)-2-((3S)-3-{[(6-chloro-2-naphthyl)sulfonyl]amino}-2-oxopyrrolidin-1-yl)propanoate(0.07 g) in THF (0.5 ml) was treated with diisopropyl azodicarboxylate(0.06 ml), 3-furfuryl alcohol (0.030 g) and tributylphosphine (0.075 ml)and shaken at room temperature for 18 h. The mixture was concentratedunder reduced pressure and the residue purified by Biotage™chromatography (eluting with cyclohexane:ethyl acetate 3:1) to give thetitle compound (0.015 g) as a colourless gum.

Mass spectrum: Found: MH⁺ 533

Using similar chemistry, but selecting the appropriate startingmaterials the following were prepared:

Intermediate 30 tert-Butyl(2S)-2-{(3S)-3-[[(6-chloro-2-naphthyl)sulfonyl](1,3-thiazol-2-ylmethyl)amino]-2-oxopyrrolidin-1-yl}propanoate

Mass spectrum: Found: MH⁺ 550

Intermediate 31(2S)-2-{(3S)-3-[[(6-Chloro-2-naphthyl)sulfonyl](1,3-thiazol-2-ylmethyl)amino]-2-oxopyrrolidin-1-yl}propanoicacid

A solution of tert-butyl(2S)-2-{(3S)-3-[[(6-chloro-2-naphthyl)sulfonyl](1,3-thiazol-2-ylmethyl)amino]-2-oxopyrrolidin-1-yl}propanoate(0.03 g) in DCM (1 ml) was treated with trifluoroacetic acid (1 ml) andstirred at room temperature for 1 h. The solution was then concentratedunder reduced pressure to give the title compound (0.019 g) as acolourless solid.

Mass spectrum: Found: MH⁺ 494

Using similar chemistry, but selecting the appropriate startingmaterials the following were prepared:

Intermediate 32(2S)-2-{(3S)-3-[[(6-Chloro-2-naphthyl)sulfonyl](2-furylmethyl)amino]-2-oxopyrrolidin-1-yl}propanoicacid mixture with(2S)-2-((3S)-3-{[(6-chloro-2-naphthyl)sulfonyl]amino}-2-oxopyrrolidin-1-yl)propanoicacid (56:44)

Mass spectrum: Found: MH⁺ 478

Intermediate 33 tert-Butyl5-chloro-2-[({(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}amino)sulfonyl]-1H-indole-1-carboxylate

1-tert-Butoxycarbonyl-5-chloroindole (0.1 g) was dissolved in anhydrousTHF (2 ml) under nitrogen and cooled to −78° C. n-Butyllithium (1.6M inhexanes, 0.273 ml) was added dropwise over 10 min. After stirring at−78° C. for 45 min, sulphur dioxide gas was bubbled through the reactionfor 5 min. The reaction mixture was allowed to reach room temperatureover 2 h and concentrated under reduced pressure to give an off-whitesolid. The solid was re-suspended in anhydrous DCM (2 ml) and treatedwith N-chlorosuccinimide (0.0584 g). The mixture was then stirred for 1h at room temperature and any remaining white solid removed byfiltration. Half of this filtrate was treated with pyridine (0.017 ml)and Intermediate 40 (0.022 g). The reaction mixture was stirred at 40°C. for 5 h and then 72 h at 30° C. in a sealed vessel. The reactionmixture was washed with water, the organic phase separated and dried(over magnesium sulphate), and evaporated under a stream of nitrogen togive a residue which was purified by mass directed preparative h.p.l.c.to give the title compound (0.011 g) as a colourless glass.

Mass spectrum: Found: MH⁺ 555

Intermediate 34N-{(3S)-1-[(1S)-1-Methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide

2-Chloroethanesulfonyl chloride (0.284 ml) was added dropwise to amixture of Intermediate (0.436 g) and N,N-di-isopropylethylamine (0.938ml) in dry acetonitrile (6 ml) at 0° C. over 2 min. The mixture wasallowed to reach room temperature and stirred for 3 days, after whichthe reaction was quenched with water and concentrated under reducedpressure to give a brown residue. This residue was partitioned betweenethyl acetate and water. The combined organic extracts were dried (overmagnesium sulphate) and concentrated under reduced pressure to give abrown foam which was purified by SPE (silica, eluting with ethylacetate:cyclohexane 1:1, ethyl acetate and then ethyl acetate:methanol19:1) to give the title compound (0.227 g) as a clear film.

Mass Spectrum: Found: MH⁺ 332

Intermediate 35 tert-Butyl(2S)-2-((3S)-3-{[(5′-chloro-2,2′-bithien-5-yl)sulfonyl]amino}-2-oxopyrrolidin-1-yl)propanoate

A solution of tert-butyl(2S)-2-[(3S)-3-amino-2-oxopyrrolidin-1-yl]propanoate (0.337 g) inacetonitrile (20 ml) was treated with triethylamine (0.41 ml) and5′-chloro-2,2′-bithiophene-5-sulfonyl chloride² (0.372 g) and stirred atroom temperature for 17 h. The mixture was concentrated under reducedpressure and the residue purified using SPE (aminopropyl, eluting withmethanol) to give the title compound (0.651 g) as a brown oil.

Mass spectrum: Found: MH⁺ 491

Using similar chemistry and Intermediate 9, the following were prepared:

Intermediate 36 tert-Butyl(2S)-2-[(3S)-3-({[(E)-2-(4-chlorophenyl)ethenyl]sulfonyl}amino)-2-oxopyrrolidin-1-yl]propanoate

Mass spectrum: Found: MH⁺ 429

Intermediate 37 tert-Butyl(2S)-2-[(3S)-3-{(2-amino-2-oxoethyl)[(E)-2-(4-chlorophenyl)ethenyl]sulfonyl}amino)-2-oxopyrrolidin-1-yl]propanoate

Using Intermediate 36, and the synthetic procedure described forIntermediate 22, the title compound was similarly prepared.

Mass spectrum: Found: MH⁺ 487

Intermediate 38 tert-Butyl(2S)-2-((3S)-3-{(2-amino-2-oxoethyl){[(5′-chloro-2,2′-bithien-5-yl)sulfonyl]amino}-2-oxopyrrolidin-1-yl)propanoate

Using Intermediate 35, and the synthetic procedure described forIntermediate 22, the title compound was similarly prepared.

Mass spectrum: Found: MH⁺ 548

Intermediate 39 Benzyl(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-ylcarbamate

(2S)-2-((3S)-3-{[(Benzyloxy)carbonyl]amino}-2-oxopyrrolidin-1-yl)propanoicacid (84.5 g) was dissolved in DMF (2 l) andO-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate(161 g) was added, followed by N,N-diisopropylethylamine (92 m)) andmorpholine (46 ml). The mixture was stirred under nitrogen for 2.5 h,and saturated aqueous ammonium chloride was added. The mixture wasstirred for 15 min then partitioned between water and ethyl acetate. Theseparated organic phase was washed with lithium chloride (10% byweight), followed by saturated sodium bicarbonate and brine. The organiclayer was dried (over sodium sulphate) and concentrated under reducedpressure to give the title compound (65 g) as a yellow solid.

Mass spectrum: Found: MH⁺ 376

Intermediate 40(3S)-3-Amino-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-pyrrolidin-2-one

A mixture of benzyl(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-ylcarbamate(20 g), 10% palladium on carbon (2 g) and ethanol (1.3 l) was stirredunder an atmosphere of hydrogen for 16 h. The reaction mixture wasfiltered through Celite™ and the filtrate was concentrated under reducedpressure to give the title compound (12.3 g) as a pale white oil.

¹H NMR (D₄MeOH): δ 5.05 (1H, dd), 3.59 (9H, m), 3.37 (2H, m), 2.42 (1H,m), 1.75 (1H, m), 1.30 (3H, d) ppm.

Intermediate 41 tert-Butyl(2S)-2-((3S)-3-{[(2-methyl-1,3-thiazol-4-yl)methyl]amino}2-oxopyrrolidin-1-yl)propanoate

A solution of 2-methyl-1,3-thiazole-4-carbaldehyde (0.028 g) in DCM (2ml) was treated with Intermediate 9 (0.05 g) followed by acetic acid(0.013 ml) and tetramethylammonium triacetoxyborohydride (0.116 g), andthe resultant mixture stirred at room temperature for 66 h. The reactionmixture was partitioned between water and DCM. The organic layer wasseparated, dried (over magnesium sulphate) and concentrated underreduced pressure to give the title compound (0.07 g) as an oil.

Mass spectrum: Found: MH⁺ 340

Using similar chemistry, but selecting the appropriate startingmaterials the following were prepared:

Intermediate 42 tert-Butyl(2S)-2-{(3S)-2-oxo-3-[(pyridin-4-ylmethyl)amino]pyrrolidin-1-yl}propanoate

Mass spectrum: Found: MH⁺ 320

Intermediate 43 tert-Butyl(2S)-2-{(3S)-2-oxo-3-[(pyridin-2-ylmethyl)amino]pyrrolidin-1-yl}propanoate

Mass spectrum: Found: MH⁺ 320

Intermediate 44 tert-Butyl(2S)-2-((3S)-3-{[(6-chloro-2-naphthyl)sulfonyl][(2-methyl-1,3-thiazol-4-yl)methyl]amino}-2-oxopyrrolidin-1-yl)propanoate

Using Intermediate 41 and the synthetic procedure described forIntermediate 14, the title compound was similarly prepared.

Mass spectrum: Found: MH⁺ 564

Intermediate 45 tert-Butyl(2S)-2-{(3S)-3-[[(6-chloro-2-naphthyl)sulfonyl](pyridin-4-ylmethyl)amino]-2-oxopyrrolidin-1-yl}propanoate

Using Intermediate 42 and the synthetic procedure described forIntermediate 14, the title compound was similarly prepared.

Mass spectrum: Found: MH⁺ 544

Intermediate 46 tert-Butyl(2S)-2-{(3S)-3-[[(6-chloro-2-naphthyl)sulfonyl](pyridin-2-ylmethyl)amino]-2-oxopyrrolidin-1-yl}propanoate

Using Intermediate 43 and the synthetic procedure described forIntermediate 14, the title compound was similarly prepared.

Mass spectrum: Found: MH⁺ 544

Intermediate 47(2S)-2-((3S)-3-{[(6-Chloro-2-naphthyl)sulfonyl][(2-methyl-1,3-thiazol-4-yl)methyl]amino}-2-oxopyrrolidin-1-yl)propanoicacid

Using Intermediate 44 and the synthetic procedure described forIntermediate 13, the title compound was similarly prepared.

Mass spectrum: Found: MH⁺ 508

Intermediate 48(2S)-2-{(3S)-3-[[(6-Chloro-2-naphthyl)sulfonyl](pyridin-4-ylmethyl)amino]-2-oxopyrrolidin-1-yl}propanoicacid hydrochloride

Using Intermediate 45 and the synthetic procedure described forIntermediate 13, the title compound was similarly prepared.

Mass spectrum: Found: MH⁺ 488

Intermediate 49(2S)-2-{(3S)-3-[[(6-Chloro-2-naphthyl)sulfonyl](pridin-2-ylmethyl)amino]-2-oxopyrrolidin-1-yl}propanoicacid hydrochloride

Using Intermediate 46 and the synthetic procedure described forIntermediate 13, the title compound was similarly prepared.

Mass spectrum: Found: MH⁺ 488

Intermediate 50 5-Chloro-1-benzofuran

To a solution of 5-chloro-1-benzofuran-2-carboxylic acid (0.2 g) in1-methyl-2-pyrrolidinone (2 ml) was added copper granules (0.2 g). Thereaction mixture was heated at 250° C. for 3.5 min in a microwave. Thereaction vessel was cooled to room temperature and the mixture combinedwith four other similar mixtures and the combined mixtures partitionedbetween water and diethyl ether. The organic layer was washed with waterand brine, dried (over magnesium sulphate) and concentrated underreduced pressure to give the title compound (0.65 g) as a yellow oil.

Gas-chromatography electron-ionisation spectrum: Found: M+152, Rt 5.72min

Intermediate 51 5-Chloro-1-benzofuran-2-sulfonyl chloride

n-Butyl lithium (1.6M in hexanes, 0.045 ml) was added to a cooled (−78°C.) solution of Intermediate 50 (0.11 g) in anhydrous THF (5 ml) over 5min. The reaction was stirred for a further 5 min, warmed to −45° C. andstirred for 40 min. The mixture was cooled to −70° C. and sulphurdioxide gas bubbled into the vessel over 7 min. The solution was allowedto warm to room temperature over 45 min, and then concentrated underreduced pressure to give a yellow gum. To a suspension of the gum inanhydrous DCM (4 ml) was added N-chlorosuccinimide (0.118 g) and themixture stirred at room temperature for 75 min. The solution wasfiltered, and the filtrate concentrated under reduced pressure to givethe title compound (0.093 g) as a yellow solid.

Mass Spectrum: Found: MH⁺ 260

Intermediate 52 2-Chloro-4-ethenylphenol

To a slurry of methyltriphenylphosphonium bromide (0.23 g) in dry THF (5ml) under nitrogen at −78° C., n-butyl lithium (1.6M in hexanes, 0.37ml) was added dropwise over 2 min. The mixture was allowed to warm to 0°C., stirred for 20 min, cooled to −78° C. and a solution of3-chloro-4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]benzaldehyde* (0.134g) in dry THF (5 ml) added. The reaction mixture was allowed to reachroom temperature overnight and quenched with saturated aqueous ammoniumchloride. The resultant mixture was extracted with diethyl ether and thecombined organic extracts were concentrated under reduced pressure. Theresidue was purified using SPE (silica, eluting with cyclohexane,followed by 5% to 25% ethyl acetate:cyclohexane) to give the titlecompound (0.049 g) as an oil.*Boukouvalas, J; Maltais, F; Lachance, N., Tetrahedron Lett. (1994),35(43), 7897-900.

H.p.l.c. (1) Rt 3.26 min

Intermediate 53 tert-Butyl (2-chloro-4-vinylphenoxy)diphenylsilane

A mixture of Intermediate 52 (0.038 g), imidazole (0.042 g) andtert-butyldiphenylsilyl chloride (0.083 ml) was stirred in dry DMF (0.5ml) at room temperature under nitrogen for 20 h. The mixture wasquenched with water, extracted with diethyl ether, dried (over magnesiumsulphate), filtered and concentrated under reduced pressure. Theresultant oil was purified using SPE (silica, eluting with cyclohexanefollowed by 5% to 20% ethyl acetate:cyclohexane) to give the titlecompound (0.102 g) as an oil.

H.p.l.c. (1) Rt 4.71 min

Intermediate 54 3-{[tert-Butyl(dimethyl)silyl]oxy}-4-chlorobenzaldehyde

A mixture of 4-chloro-3-hydroxy-benzaldehyde* (0.354 g),4-N,N-dimethylaminopyridine (0.028 g), tert-butyldimethylsilyl chloride(0.409 g) and triethylamine (0.473 ml) in DCM (15 ml) was stirred atroom temperature under nitrogen for 19 h. The mixture was quenched withsaturated aqueous sodium bicarbonate and extracted with diethyl ether.The combined organic extracts were concentrated under reduced pressureto give an oil which was purified using SPE (silica, eluting withcyclohexane followed by 10% to 30% ethyl acetate:cyclohexane) to givethe title compound (0.42 g) as an oil.*Kelley, J; Linn, J; Selway, J. W. T., J. Med. Chem. (1989), 32(8),1757-63.

H.p.l.c. (1) Rt 4.11 min

Intermediate 55(E)-2-(3-{[tert-Butyl(diphenyl)silyl]oxy}-4-chlorophenyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide

Sulphuryl chloride (0.103 ml) was added dropwise to DMF (0.116 ml) at 0°C. under nitrogen, over 5 min. The mixture was allowed to reach roomtemperature and stirred for 30 min. Intermediate 57 (0.293 g) incyclohexane (0.2 ml) was added in one portion and the resultant mixturewas heated at 90° C. for 6 h. The cooled mixture was poured onto crushedice, extracted with diethyl ether, dried (over sodium sulphate) andconcentrated under reduced pressure. This crude sulfonyl chloride wastreated with Intermediate 40 (0.134 g), 4-dimethylaminopyridine (0.0068g), N,N′-di-isopropylethylamine (0.192 ml) in dry DCM (5 ml), and afterstirring for 3 days at room temperature under nitrogen, the mixture wasconcentrated under reduced pressure. The resultant solution was washedwith water and filtered through a hydrophobic frit. The filtrate wasconcentrated under reduced pressure to give an oil, which was purifiedby SPE (silica, eluting with cyclohexane:ethyl acetate 19:1 and then10:1) followed by mass directed preparative h.p.l.c. to give the titlecompound (0.0078 g) as a colourless gum.

Mass spectrum: Found: MH⁺ 696

Intermediate 56 2-Chloro-5-vinylphenol

The title compound was prepared using Intermediate 54 and the syntheticprocedure described for Intermediate 52.

H.p.l.c. (1) Rt 3.22 min

Intermediate 57 tert-Butyl (2-chloro-5-vinylphenoxy)diphenylsilane

The title compound was prepared using Intermediate 56 and the syntheticprocedure described for Intermediate 53.

H.p.l.c. (1) Rt 4.68 min

Intermediate 58(3S)-3-{[(6-Chloro-1,3-benzothiazol-2-yl)thio]amino}-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]pyrrolidin-2-one

N-Chlorosuccinimide (0.37 g) was added to4-chloro-2-mercaptobenzothiazole (0.5 g) in DCM (15 ml) under nitrogen,and stirred at room temperature for 3 h. A solution of Intermediate 40(0.569 g) and triethylamine (1.04 ml) in anhydrous DCM (5 ml) were addedand the resulting mixture stirred at room temperature under nitrogen for2 h. The solution was filtered and the filtrate was diluted with DCM.The organic solution was washed with water and brine, dried (overmagnesium sulphate) and concentrated under reduced pressure. The residuewas purified by SPE (silica, eluting with cyclohexane:ethyl acetate 1:1increasing polarity to ethyl acetate:methanol 19:1) to give the titlecompound (0.3 g) as a white solid.

Mass spectrum: Found: MH⁺ 441

Intermediate 59 5-Chlorothieno[2,3-b]pyridine-2-sulfonyl chloride

n-Butyl lithium (1.6M in hexanes, 0.37 ml) was added to a cooled (−78°C.) solution of 5-chlorothieno[2,3-b]pyridine* (0.100 g) in anhydrousTHF (5 ml) over 15 min. The reaction was stirred for a further 5 min,warmed to −45° C. and stirred for 40 min. The mixture was cooled to −70°C. and sulphur dioxide gas was bubbled into the vessel over 10 min. Thereaction was allowed to reach room temperature over 45 min, and thenconcentrated under reduced pressure. The residue was dissolved inanhydrous DCM (5 ml), treated with N-chlorosuccinimide (0.097 g) andstirred at room temperature for 75 min. The solution was filtered, andthe filtrate concentrated under reduced pressure to give the titlecompound (0.198 g) as a yellow solid.*Klemm. L. H. et. al., J. Heterocycl. Chem. (1968), 5(6), 773-8.

Mass Spectrum: Found: MH⁺ 277 for dimethylamine quenched mass spectrumsample

Intermediate 60 5-Chlorothieno[3,2-b]pyridine-2-sulfonyl chloride

5-Chlorothieno[3,2-b]pyridine* (0.2 g) was dissolved in anhydrous THF(10 ml) under nitrogen and cooled to −70° C. n-Butyllithium (1.6M inhexanes, 0.780 ml) was added dropwise over 10 min and the mixturestirred for a further 5 min. The mixture was warmed to −50° C. andstirred for 55 min. The reaction was cooled to −70° C., and sulphurdioxide gas was bubbled through the reaction for 10 min. The reactionwas allowed to warm to room temperature and concentrated under reducedpressure to give a yellow residue which was re-suspended in anhydrousDCM (6 ml) and treated with N-chlorosuccinimide (0.189 g). The mixturewas stirred for 2 h at room temperature and any remaining solid removedby filtration. The filtrate was concentrated under reduced pressure togive the title compound (0.153 g) as a white solid.*Barker. J. N, et. al., J. Chem. Res. (1984), (3), 771-795.

Mass Spectrum: Found: MH⁺ 277 for dimethylamine quenched mass spectrumsample

Example 16-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide

To a solution of(2S)-2-((3S)-3-{[(6-chloro-2-naphthyl)sulfonyl]amino}-2-oxopyrrolidin-1-yl)propanoicacid [Intermediate 17] (0.105 g) in DCM (10 ml) were added1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (0.152 g),HOBT (0.107 g) and triethylamine (0.222 ml) and the mixture was stirredat room temperature for 30 min. Morpholine (0.07 ml) was added and theresultant mixture stirred at room temperature for 16 h. The mixture waspartitioned between DCM and water. The aqueous layer was re-extractedwith DCM and the combined, dried (over magnesium sulphate) organicextracts were concentrated under reduced pressure. The residue waspurified using SPE (silica, eluting with cyclohexane:ethyl acetate 5:1,and ethyl acetate) to give the title compound (0.1 g) as a white solid.

Mass spectrum: Found: MH⁺ 466

H.p.l.c. (1) Rt 3.13 min

¹H NMR (D₄MeOH): δ 8.54 (1H, br.s), 8.08-7.96 (4H, m), 7.63 (1H, dd),5.00 (1H, q), 4.18 (1H, dd), 3.69-3.46 (9H, m), 3.31-3.29 (1H, m), 2.27(1H, m), 1.77 (1H, m), 1.26 (3H, d) ppm.

Using similar chemistry, but selecting the appropriate staring materialsthe following were prepared:

Example 26-Chloro-N-{(3S)-1-[(1S)-2-(2,6-dimethylmorpholin-4-yl)-1-methyl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide

Mass spectrum: Found: MH⁺ 494

H.p.l.c. (1) Rt 3.16 min

Example 36-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-(3-methylmorpholin-4-yl)-2-oxoethyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide

Mass spectrum: Found: MH⁺ 480

H.p.l.c. (1) Rt 3.23 min

Example 46-Chloro-N-((3S)-1-{(1S)-1-methyl-2-oxo-2-[3-(pyrrolidin-1-ylcarbonyl)morpholin-4-yl]ethyl}-2-oxopyrrolidin-3-yl)naphthalene-2-sulfonamide

Mass spectrum: Found: MH⁺ 563

H.p.l.c. (1) Rt 3.08 min

Example 56-Chloro-N-[(3S)-1-((1S)-1-methyl-2-{2-[(methylsulfonyl)methyl]morpholin-4-yl}-2-oxoethyl)-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide

Mass spectrum: Found: MH⁺ 558

H.p.l.c. (1) Rt 3.17 min

Example 66-Chloro-N-((3S)-1-{(1S)-2-[2-(methoxymethyl)morpholin-4-yl]-1-methyl-2-oxoethyl}-2-oxopyrrolidin-3-yl)naphthalene-2-sulfonamide

Mass spectrum: Found: MH⁺ 510

H.p.l.c. (1) Rt 3.02 min

Example 7 and Example 84-[(2S)-2-((3S)-3-{[(6-Chloro-2-naphthyl)sulfonyl]amino}-2-oxopyrrolidin-1-yl)propanoyl]-N-methylmorpholin-2-carboxamide[Isomer 1 and Isomer 2]

Isomer 1

Mass spectrum: Found: MH⁺ 523

H.p.l.c. (1) Rt 2.93 min

Isomer 2

Mass spectrum: Found: MH⁺ 523

H.p.l.c. (1) Rt 2.96 min

Example 96-Chloro-N-((3S)-1-{(1S)-1-methyl-2-oxo-2-[2-(pyrrolidin-1-ylcarbonyl)morpholin-4-yl]ethyl}-2-oxopyrrolidin-3-yl)naphthalene-2-sulfonamide

Mass spectrum: Found: MH⁺ 563

H.p.l.c. (1) Rt 3.04 min

Example 104-[(2S)-2-((3S)-3-{[(6-Chloro-2-naphthyl)sulfonyl]amino}-2-oxopyrrolidin-1-yl)propanoyl]-N,N-dimethylmorpholine-2-carboxamide

Mass spectrum: Found: MH⁺ 537

H.p.l.c. (1) Rt 2.96 min

Example 11, Example 12 and Example 134-(2S)-2-((3S)-3-{[(6-Chloro-2-naphthyl)sulfonyl]amino}-2-oxopyrrolidin-1-yl)propanoyl]-N-(2-hydroxypropyl)morpholine-2-carboxamide[Isomer 1, Isomer 2 and Isomer 3]

Isomer 1

Mass spectrum: Found: MH⁺ 567

H.p.l.c. (1) Rt 2.92 min

Isomer 2

Mass spectrum: Found: MH⁺ 567

H.p.l.c. (1) Rt 2.91 min

Isomer 3

Mass spectrum: Found: MH⁺ 567

H.p.l.c. (1) Rt 2.92 min

Example 144-[(2S)-2-((3S)-3-{[(6-Chloro-2-naphthyl)sulfonyl]amino}-2-oxopyrrolidin-1-yl)propanoyl]-N,N-diisopropylmorpholine-2-carboxamide

Mass spectrum: Found: MH⁺ 593

H.p.l.c. (1) Rt 3.4 min

Example 156-Chloro-N-((3S)-1-{(1S)-1-methyl-2-oxo-2-[2-(piperidin-1-ylcarbonyl)morpholin-4-yl]ethyl}-2-oxopyrrolidin-3-yl)naphthalene-2-sulfonamide

Mass spectrum: Found: MH⁺ 577

H.p.l.c. (1) Rt 3.21 min

Example 166-Chloro-N-[(3S)-1-((1S)-1-methyl-2-{2-[(methylamino)methyl]morpholin-4-yl}-2-oxoethyl)-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamideformate

Mass spectrum: Found: MH⁺ 509

H.p.l.c. (1) Rt 2.58 min

Example 176-Chloro-N-((3S)-1-{(1S)-1-methyl-2-oxo-2-[2-(pyrrolidin-1-ylmethyl)morpholin-4-yl]ethyl}-2-oxopyrrolidin-3-yl)naphthalene-2-sulfonamideformate

Mass spectrum: Found: MH⁺ 549

H.p.l.c. (1) Rt 2.58 min

Example 186-Chloro-N-{(3S)-1-[(1S)-2-(2-{[(2-hydroxypropyl)amino]methyl}morpholin-4-yl)-1-methyl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamideformate

Mass spectrum: Found: MH⁺ 553

H.p.l.c. (1) Rt 2.55 min

Example 19 and Example 206-Chloro-N-[(3S)-1-((1S)-2-{2-[(dimethylamino)methyl]morpholin-4-yl}-1-methyl-2-oxoethyl)-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamideformate [Isomer 1 and Isomer 2]

Isomer 1

Mass spectrum: Found: MH⁺ 523

H.p.l.c. (1) Rt 2.54 min

Isomer 2

Mass spectrum: Found: MH⁺ 523

H.p.l.c. (1) Rt 2.55 min

Example 216-Chloro-N-[(3S)-1-((1S)-2-{2-[(diisopropylamino)methyl]morpholin-4-yl}-1-methyl-2-oxoethyl)-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamideformate

Mass spectrum: Found: MH⁺ 579

H.p.l.c. (1) Rt 2.67 min

Example 226-Chloro-N-((3S)-1-{(1S)-1-methyl-2-oxo-2-[2-(piperidin-1-ylmethyl)morpholin-4-yl]ethyl}-2-oxopyrrolidin-3-yl)naphthalene-2-sulfonamideformate

Mass spectrum: Found: MH⁺ 563

H.p.l.c. (1) Rt 2.62 min

Example 236-Chloro-N-((3S)-1-{(1S)-2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-1-methyl-2-oxoethyl}-2-oxopyrrolidin-3-yl)naphthalene-2-sulfonamide

Mass spectrum: Found: MH⁺ 494

H.p.l.c. (1) Rt 3.15 min

Example 246-Chloro-N-{(3R)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide

Mass spectrum: Found: MH⁺ 466

H.p.l.c. (1) Rt 2.96 min

Example 255′-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-2,2′-bithiophene-5-sulfonamide

tert-Butyl(2S)-2-((3S)-3-{[(5′-chloro-2,2′-bithien-5-yl)sulfonyl]amino}-2-oxopyrrolidin-1-yl)propanoate[Intermediate 35] (0.217 g) was dissolved in DCM (2 ml) and treated withtrifluoroacetic acid (2 ml) and stirred at room temperature for 2 h. Themixture was then concentrated under reduced pressure to give an oilwhich was subsequently dissolved in DCM (5 ml) and treated with1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (0.256 g),HOBT (0.184 g) and triethylamine (0.375 ml). After the solution had beenstirred at room temperature for 30 min, morpholine (0.117 ml) was addedand the resultant mixture stirred for a further 20 h. The mixture wasconcentrated under reduced pressure and the residue partitioned betweenDCM and water. The organic component was washed with water and brine,and concentrated under reduced pressure. The residue was purified usingSPE (silica, eluting with cyclohexane; cyclohexane:ethyl acetate 4:1,1:1, 1:4; ethyl acetate; methanol:ethyl acetate 1:10; methanol) to givethe title compound (0.078 g) as a white solid.

Mass spectrum: Found: MH⁺ 504

H.p.l.c. (1) Rt 3.17 min

¹H NMR (D₄MeOH): δ 7.61 (1H, d), 7.23 (1H, d), 7.22 (1H, d), 7.03 (1H,d), 5.04 (1H, q), 4.21 (1H, dd), 3.69-3.46 (9H, m), 3.39-3.35 (1H, m),2.39 (1H, m), 1.86 (1H, m), 1.30 (3H, d) ppm.

Example 26(E)-2-(4-Chlorophenyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide

Using Intermediate 36 and the synthetic procedure described for Example25, the title compound was prepared.

Mass spectrum: Found: MH⁺ 442

H.p.l.c. (1) Rt 2.86 min

¹H NMR (CDCl₃): δ 7.46 (1H, d), 7.44 (2H, d), 7.38 (2H, d), 6.89 (1H,d), 5.35 (1H, br.d), 5.05 (1H, q), 4.00 (1H, m), 3.69-3.48 (9H, m), 3.35(1H, m), 2.62 (1H, m), 2.06 (1H, m), 1.33 (3H, d) ppm.

Example 27N2-{[(E)-2-(4-Chlorophenyl)ethenyl]sulfonyl}-N2-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinamide

Using Intermediate 37 and the synthetic procedure described for Example25, the title compound was prepared.

Mass spectrum: Found: MH⁺ 499

H.p.l.c. (1) Rt 2.81 min

Example 28N2-[(5′-Chloro-2,2′-bithien-5-yl)sulfonyl]-N2-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinamide

Using Intermediate 38 and the synthetic procedure described for Example25, the title compound was prepared.

Mass spectrum: Found: MH⁺ 561

H.p.l.c. (1) Rt 2.96 min

Example 295′-Chloro-N-(cyanomethyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-2,2′-bithiophene-5-sulfonamide

Using Example 25 and the synthetic procedure described for Example 50,the title compound was prepared.

Mass spectrum: Found: MH⁺ 543

H.p.l.c. (1) Rt 3.34 min

Using similar chemistry, but selecting the appropriate staring materialsthe following were prepared:

Example 30 MethylN-[(5′-chloro-2,2′-bithien-5-yl)sulfonyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinate

Mass spectrum: Found: MH⁺ 576

H.p.l.c. (1) Rt 3.34 min

Example 315′-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-oxobutyl)-2,2′-bithiophene-5-sulfonamide

Mass spectrum: Found: MH⁺ 574

H.p.l.c. (1) Rt 3.4 min

Example 32N-[(5′-Chloro-2,2′-bithien-5-yl)sulfonyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycine

Using standard alkaline hydrolysis conditions, the title compound wasprepared from Example 30.

Mass spectrum: Found: MH⁺ 562

H.p.l.c. (1) Rt 3.21 min

Example 33(E)-2-(4-Chlorophenyl)-N-(cyanomethyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide

Using Example 26 and bromoacetonitrile, and the synthetic proceduredescribed for Example 50, the title compound was prepared.

Mass spectrum: Found: MH⁺ 481

H.p.l.c. (1) Rt 3.05 min

Using similar chemistry, but selecting the appropriate startingmaterials the following were prepared:

Example 34(E)-2-(4-Chlorophenyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-oxobutyl)ethenesulfonamide

Mass spectrum: Found: MH⁺ 512

H.p.l.c. (1) Rt 3.13 min

Example 35 MethylN-{[(E)-2-(4-chlorophenyl)ethenyl]sulfonyl}-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinate

Mass spectrum: Found: MH⁺ 514

H.p.l.c. (1) Rt 3.05 min

Example 36N-{[(E)-2-(4-Chlorophenyl)ethenyl]sulfonyl}-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycine

Using standard alkaline hydrolysis conditions, the title compound wasprepared from Example 35.

Mass spectrum: Found: MH⁺ 500

H.p.l.c. (1) Rt 2.9 min

Example 376-Chloro-N-(3-furylmethyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide

A solution of6-chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide[Example 1] (0.015 g) in THF (0.5 ml) was treated with diisopropylazodicarboxylate (0.01 ml), 3-furanmethanol (0.004 ml) andtri-n-butylphosphine (0.008 ml) and shaken at room temperature for 60 h.The mixture was concentrated under reduced pressure and the residuepurified by mass directed preparative h.p.l.c. to give the titlecompound (0.015 g) as a colourless gum.

Mass spectrum: Found: MH⁺ 546

H.p.l.c. (1) Rt 3.33 min

Using similar chemistry, but selecting the appropriate startingmaterials the following were prepared:

Example 386-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(pyridin-3-ylmethyl)naphthalene-2-sulfonamideformate

The title compound was isolated from a crude reaction mixture using massdirected preparative h.p.l.c.

Mass spectrum: Found: MH⁺ 557

H.p.l.c. (1) Rt 2.9 min

Example 396-Chloro-N-ethyl-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide

Mass spectrum: Found: MH⁺ 494

H.p.l.c. (1) Rt 3.32 min

Example 406-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-oxobutyl)naphthalene-2-sulfonamide

To a solution of(2S)-2-{(3S)-3-[[(6-chloro-2-naphthyl)sulfonyl](2-oxobutyl)amino]-2-oxopyrrolidin-1-yl}propanoicacid [Intermediate 25] (0.035 g) in DCM (2 ml) were added1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (0.044 g),HOBT (0.031 g) and triethylamine (0.064 ml) and the mixture was stirredat room temperature for 30 min. Morpholine (0.02 ml) was added and theresultant mixture stirred at room temperature for 16 h. The mixture waspartitioned between DCM and water. The aqueous layer was re-extractedwith DCM and the combined, dried (over magnesium sulphate) organicextracts were concentrated under reduced pressure. The residue waspurified using mass directed preparative h.p.l.c. to give the titlecompound (0.008 g) as a white solid.

Mass spectrum: Found: MH⁺ 536

H.p.l.c. (1) Rt 3.20 min

Using similar chemistry, but selecting the appropriate startingmaterials the following were prepared:

Example 41N-2-[(6-Chloro-2-naphthyl)sulfonyl]-N-2-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinamide

The title compound was prepared from Intermediate 26.

Mass spectrum: Found: MH⁺ 523

H.p.l.c. (1) Rt 2.87 min

Example 426-Chloro-N-(2-furylmethyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide

The title compound was prepared from Intermediate 32.

Mass spectrum: Found: MH⁺ 546

H.p.l.c. (1) Rt 3.33 min

Example 436-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(1,3-thiazol-2-ylmethyl)naphthalene-2-sulfonamide

The title compound was prepared from Intermediate 31.

Mass spectrum: Found: MH⁺ 563

H.p.l.c. (1) Rt 3.18 min

Example 44N2-[(6-Chloro-2-naphthyl)sulfonyl]-N2-((3S)-1-{(1S)-2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-1-methyl-2-oxoethyl}-2-oxopyrrolidin-3-yl)glycinamide

The title compound was prepared from Intermediate 26.

Mass spectrum: Found: MH⁺ 551

H.p.l.c. (3) Rt 13.4 min

Example 456-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-[(2-methyl-1,3-thiazol-4-yl)methyl]naphthalene-2-sulfonamide

The title compound was prepared from Intermediate 47.

Mass spectrum: Found: MH⁺ 577

H.p.l.c. (1) Rt 3.24 min

Example 466-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(pyridin-2-ylmethyl)naphthalene-2-sulfonamideformate

The title compound was prepared from Intermediate 49.

Mass spectrum: Found: MH⁺ 563

H.p.l.c. (1) Rt 3.62 min

Example 476-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(pyridin-4-ylmethyl)naphthalene-2-sulfonamideformate

The title compound was prepared from Intermediate 48.

Mass spectrum: Found: MH⁺ 557

H.p.l.c. (1) Rt 2.83 min

Example 486-Chloro-N-{(3S)-1-[(1R)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide

To a solution of(2R)-2-((3S)-3-{[(6-chloro-2-naphthyl)sulfonyl]amino}-2-oxopyrrolidin-1-yl)propanoicacid [Intermediate 28] (0.037 g) in DCM (1.0 ml) were added1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (0.036 g),HOBT (0.025 g) and triethylamine (0.026 ml) and the mixture was stirredat room temperature for 5 min. Morpholine (0.012 ml) was added and theresultant mixture stirred at room temperature for 15.5 h. The mixturewas partitioned between DCM and saturated sodium bicarbonate solutionand then passed through a hydrophobic frit. The organic extract wasconcentrated under reduced pressure and the residue was partiallypurified using preparative thin layer chromatography (20 cm×20 cm 1 mmthick Whatman PKF₂₅₆ SiO₂ plate, eluting with hexane:ethyl acetate 1:5)to give an impure sample of the title compound. This sample wasrepurified using preparative thin layer chromatography (20 cm×20 cm 1 mmthick Whatman PKF₂₅₆ SiO₂ plate, eluting with hexane:ethyl acetate 1:8)to give the title compound (0.036 g) as a white solid.

Mass spectrum: Found: MH⁺ 466

H.p.l.c. (1) Rt 2.95 min

Example 496-Chloro-N-methyl-N-{(3S)-1-[(1R)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide

The title compound was prepared using Intermediate 27 and the syntheticprocedure described for Example 1.

Mass spectrum: Found: MH⁺ 479

H.p.l.c. (1) Rt 3.18 min

Example 506-Chloro-N-(cyanomethyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide

A solution of6-chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide[Example 1] (0.01 g) in THF (2 ml) was cooled to −78° C. under nitrogen,and treated with lithium bis(trimethylsilyl)amide (1.0M solution in THF;0.026 ml), followed by bromoacetonitrile (0.013 g). The resultantsolution was allowed to reach room temperature and stirred for a further16 h. The mixture was then cooled to −78° C. and further lithiumbis(trimethylsilyl)amide (0.026 l) added. After reaching roomtemperature, the reaction mixture was stirred for a further 18 h andthen quenched by the addition of methanol (1 ml). The resultant solutionwas concentrated under reduced pressure and the residue purified by massdirected preparative h.p.l.c. to give the title compound (0.003 g) as awhite solid.

Mass spectrum: Found: MH⁺ 505

H.p.l.c. (1) Rt 3.16 min

Similarly prepared using commercially available alkyl halides, were:

Example 516-Chloro-N-methyl-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide

Mass spectrum: Found: MH⁺ 480

H.p.l.c. (1) Rt 3.11 min

Example 526-Chloro-N-(3,3-dimethyl-2-oxobutyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide

Mass spectrum: Found: MH⁺ 564

H.p.l.c. (1) Rt 3.39 min

Example 53N2-[(6-Chloro-2-naphthyl)sulfonyl]-N1-methyl-N2-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinamide

Mass spectrum: Found: MH⁺ 537

H.p.l.c. (1) Rt 2.98 min

Example 54N-Allyl-6-chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide

Mass spectrum: Found: MH⁺ 506

H.p.l.c. (1) Rt 3.26 min

Example 55 MethylN-[(6-chloro-2-naphthyl)sulfonyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinate

Mass spectrum: Found: MH⁺ 538

H.p.l.c. (1) Rt 3.12 min

Example 56 EthylN-[(6-chloro-2-naphthyl)sulfonyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinate

Mass spectrum: Found: MH⁺ 552

H.p.l.c. (1) Rt 3.36 min

Example 57 tert-ButylN-[(6-chloro-2-naphthyl)sulfonyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinate

Mass spectrum: Found: MH⁺ 580

H.p.l.c. (1) Rt 3.45 min

Example 58N-[(6-Chloro-2-naphthyl)sulfonyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycine

To a solution of methylN-[(6-chloro-2-naphthyl)sulfonyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinate[Example 55] (0.010 g) in THF (2 ml) was added lithium hydroxide (0.003g) in water (2 ml), and the resultant solution stirred for 16 h. Themixture was acidified to pH5 using hydrochloric acid (2N), and thenconcentrated under reduced pressure. The residue was purified using massdirected preparative h.p.l.c. to give the title compound (0.006 g) as awhite solid.

Mass spectrum: Found: MH⁺ 524

H.p.l.c. (1) Rt 3.00 min

Example 596-Chloro-N-{(3R)-1-[(1R)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide

Using Intermediate 19 and the procedure described for Example 1, thetitle compound was prepared.

Mass spectrum: Found: MH⁺ 466

H.p.l.c. (1) Rt 2.95 min

Example 605-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-1-benzofuran-2-sulfonamide

To a solution of(3S)-3-amino-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]pyrrolidin-2-one[Intermediate 40] (0.077 g) in anhydrous acetonitrile (2 ml) were added5-chloro-1-benzofuran-2-sulfonyl chloride [Intermediate 51] (0.043 g) inacetonitrile (2 ml) and pyridine (0.057 ml), and the mixture was stirredat room temperature for 72 h. Saturated ammonium chloride solution (2ml) was added and the resultant mixture stirred at room temperature for20 min. The mixture was concentrated under reduced pressure and theresidue partitioned between chloroform and hydrochloric acid (2M). Theorganic layer was washed with saturated sodium bicarbonate and brine.The organic layer was isolated, dried (over magnesium sulphate) andconcentrated under reduced pressure to give the title compound (0.043 g)as a white solid.

Mass spectrum: Found: MH⁺ 456

H.p.l.c. (1) Rt 2.78 min

Example 61(E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide

Route 1

To a solution of(3S)-3-amino-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]pyrrolidin-2-one[Intermediate 40] (14.9 g) in anhydrous acetonitrile (750 ml) were added(E)-2-(5-chlorothien-2-yl)ethenesulfonyl chloride (16.5 g) inacetonitrile (250 ml) and pyridine (11 ml), and the mixture was stirredat room temperature for 72 h. Saturated ammonium chloride solution wasadded and the resultant mixture stirred at room temperature for 30 min.The mixture was concentrated under reduced pressure and the residuepartitioned between chloroform and a 1:1 mixture of hydrochloric acid(2M) and water. The organic layer was washed with a 1:1 mixture ofsaturated sodium bicarbonate and water, and brine. The organic layer wasisolated, dried (over magnesium sulphate) and concentrated under reducedpressure to give the title compound (19.3 g) as a white solid.

Mass spectrum: Found: MH⁺ 448

H.p.l.c. (1) Rt 2.99 min

¹H NMR (CDCl₃): δ 7.48 (1H, d), 7.08 (1H, d), 6.90 (1H, d), 6.55 (1H,d), 5.12 (1H, br.d), 5.06 (1H, q), 3.96 (1H, m), 3.70-3.48 (9H, m), 3.35(1H, m), 2.62 (1H, m), 2.05 (1H, m), 1.34 (3H, d) ppm.

Route 2

To a mixture of Intermediate 34 (0.028 g),tris(dibenzylideneacetone)dipalladium(0) (0.0028 g) and2-(di-t-butylphosphino)biphenyl (0.0037 g) under nitrogen, was added drydioxan (0.25 ml) and the mixture was stirred for 5 min at roomtemperature. N,N-Di-isopropylethylamine (0.02 ml) followed by2-bromo-5-chlorothiophene (0.016 ml) in dry dioxan (0.25 ml) were thenadded and the resultant solution was stirred at room temperature for 19h and then heated at 80° C. for 1 h. The reaction was lowered to 60° C.and maintained at this temperature for 20 h. Evaporation of the cooledreaction mixture under a stream of nitrogen gave a residue that waspurified by SPE (silica; using an OPTIX. Gradient elution [flow rate 10ml/min; fraction size 10 ml; UV detector set at λ_(max) 254nm; 0 to 50%ethyl acetate-cyclohexane over 5 min, followed by 50% to 100% ethylacetate-cyclohexane for 11 min and then 100% ethyl acetate for 4 min])gave the title compound (0.0187 g) as a clear oil.

Using similar chemistry to that described for Example 61 Route 1, butselecting the appropriate starting materials the following wereprepared:

Example 625-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide

Mass spectrum: Found: MH⁺ 472

H.p.l.c. (1) Rt 2.9 min

¹H NMR (CDCl₃): δ 7.87 (1H, d), 7.86 (1H, m), 7.78 (1H, dm), 7.46 (1H,dd), 5.58 (1H, br.d), 5.02 (1H, q), 3.91 (1H, m), 3.69-3.44 (9H, m),3.34 (1H, m), 2.65 (1H, m), 2.10 (1H, m), 1.31 (3H, d) ppm.

Example 636-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide

Mass spectrum: Found: MH⁺ 472

H.p.l.c. (1) Rt 2.96 min

¹H NMR (CDCl₃): δ 7.89 (1H, s), 7.85 (1H, br.m), 7.81 (1H, d), 7.44 (1H,dd), 5.46 (1H, br.d), 5.01 (1H, q), 3.90 (1H, m), 3.73-3.48 (9H, m),3.34 (1H, m), 2.67 (1H, m), 2.10 (1H, m), 1.31 (3H, d) ppm.

Example 645-Chloro-3-methyl-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide

Mass spectrum: Found: MH⁺ 486

H.p.l.c. (1) Rt 3.11 min

Example 653-Cyano-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}benzenesulfonamide

Mass spectrum: Found: MH⁺ 407

H.p.l.c. (1) Rt 2.4 min

Example 664-Cyano-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}benzenesulfonamide

Mass spectrum: Found: MH⁺ 407

H.p.l.c. (1) Rt 2.4 min

Example 675-(5-Chloro-1,3,4-thiadiazol-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}thiophene-2-sulfonamide

Mass spectrum: Found: MH⁺ 506

H.p.l.c. (1) Rt 2.82 min

Example 685-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}thieno[2,3-b]pyridine-2-sulfonamide

Mass spectrum: Found: MH⁺ 473

H.p.l.c. (1) Rt 2.64 min

Example 695-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}thieno[3,2-b]pyridine-2-sulfonamide

Mass spectrum: Found: MH⁺ 473

H.p.l.c. (1) Rt 2.53 min

Example 706-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-oxobutyl)-1-benzothiophene-2-sulfonamide

Using Example 63 and 1-bromo-2-butanone, and the synthetic proceduredescribed for Example 50, the title compound was prepared.

Mass spectrum: Found: MH⁺ 542

H.p.l.c. (1) Rt 3.28 min

Using similar chemistry, but selecting the appropriate startingmaterials following was prepared:

Example 71N2-[(6-Chloro-1-benzothien-2-yl)sulfonyl]-N2-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinamide

Mass spectrum: Found: MH⁺ 529

H.p.l.c. (1) Rt 2.91 min

Example 725-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-oxobutyl)-1-benzothiophene-2-sulfonamide

Using Example 62 and 1-bromo-2-butanone, and the synthetic proceduredescribed for Example 50, the title compound was prepared.

Mass spectrum: Found: MH⁺ 542

H.p.l.c. (1) Rt 3.27 min

Using similar chemistry, but selecting the appropriate startingmaterials the following was prepared:

Example 73N2-[(5-Chloro-1-benzothien-2-yl)sulfonyl]-N2-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinamide

Mass spectrum: Found: MH⁺ 529

H.p.l.c. (1) Rt 2.85 min

Example 746-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-phenylnaphthalene-2-sulfonamide

A mixture of Example 1 (0.0206 g), phenylboronic acid (0.0162 mg),copper(II) acetate (0.016 g), triethylamine 0.123 ml) and powered 4 Åmolecular sieves (dried, 0.1 g) in dry DCM (0.5 ml) was stirred at roomtemperature for 6 days. The reaction mixture was filtered using SPE(silica, eluting with 30% methanol in ethyl acetate). The organicfraction was concentrated under reduced pressure to give a brown residuethat was purified by mass directed preparative h.p.l.c. to give thetitle compound (0.0062 g) as a gum.

Mass spectrum: Found: MH⁺ 542

H.p.l.c. (1) Rt 3.38 min

Using similar chemistry, but selecting the appropriate startingmaterials the following were prepared:

Example 756-Chloro-N-(4-fluorophenyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide

Mass spectrum: Found: MH⁺ 560

H.p.l.c. (1) Rt 3.43 min

Example 766-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-pyridin-4-ylnaphthalene-2-sulfonamide

Mass spectrum: Found: MH⁺ 543

H.p.l.c. (1) Rt 3.06 min

Example 776-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-pyridin-3-ylnaphthalene-2-sulfonamide

Mass spectrum: Found: MH⁺ 543

H.p.l.c. (1) Rt 3.10 min

Example 786-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-thien-3-ylnaphthalene-2-sulfonamide

Mass spectrum: Found: MH⁺ 548

H.p.l.c. (1) Rt 3.38 min

Example 79N2-[(6-Chloro-2-naphthyl)sulfonyl]-N2-((3S)-1-{(1S)-2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-1-methyl-2-oxoethyl}-2-oxopyrrolidin-3-yl)glycinamide

Using Intermediate 26 and the procedure described for Example 1, thetitle compound was prepared.

Mass spectrum: Found: MH⁺ 551

H.p.l.c. (1) Rt 3.02 min

Example 80(E)-2-(3-Chloro-4-hydroxyphenyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide

Sulphuryl chloride (0.036 ml) was added dropwise to DMF (0.04 ml) at 0°C. and the mixture was stirred at room temperature for 2 h. Intermediate53 (0.102 g) in cyclohexane (0.2 ml) was added in one portion and theresultant mixture was heated at 90° C. for 6 h. The cooled reactionmixture was poured onto ice and extracted with DCM. The combined organicextracts were dried (over magnesium sulphate) and concentrated underreduced pressure to give a brown oil which was treated with sulphurylchloride (0.035 ml) and triphenyl phosphine (0.103 g) in dry DCM (ca.0.5 ml). After stirring for 3 h at room temperature, the mixture wasfiltered through a SPE silica cartridge preconditioned with cyclohexane.Elution with ethyl acetate gave, after concentration under reducedpressure, an orange-brown solid which was stirred with Intermediate 40(0.04 g), 4-dimethylaminopyridine (0.021 g), N,N-di-isopropylethylamine(0.059 ml) in dry DCM (1 ml). After stirring for 3 days at roomtemperature under nitrogen, the mixture was concentrated under reducedpressure. The residue was purified initially using SPE (silica) followedby mass directed preparative h.p.l.c. to give the title compound (0.0035g) as a white solid.

Mass spectrum: Found: MH⁺ 458

H.p.l.c. (1) Rt 2.58 min

Example 81(E)-2-(4-Chloro-3-hydroxyphenyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide

To a solution of Intermediate 55 (0.0078 g) in THF (0.3 ml) at −78° C.under nitrogen, tetra n-butylammonium fluoride (1M in THF, 0.014 ml) wasadded. The mixture was allowed to warm to room temperature over 3 daysand then concentrated under reduced pressure. The residue was purifiedusing mass directed preparative h.p.l.c. to give the title compound(0.0043 g) as a clear film.

Mass spectrum: Found: MH⁺ 458

H.p.l.c. (1) Rt 2.67 min

Example 826-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-morpholin-4-ylethyl)naphthalene-2-sulfonamideformate

Example 1 (0.05 g) was dissolved in DMF (1 ml) and treated withchloroethylmorpholine hydrochloride (0.062 g) and potassium carbonate(0.093 g), and stirred at 40° C. for 2 h. The mixture was then heated at80° C. for 8 h, cooled and treated with ethyl acetate and water. Theorganic extract was dried (over magnesium sulphate) and concentratedunder reduced pressure. The residue was purified using mass directedpreparative h.p.l.c. to give the title compound (0.018 g) as a whitesolid.

Mass spectrum: Found: MH⁺ 579

H.p.l.c. (1) Rt 2.56 min

Using similar chemistry, but selecting the appropriate startingmaterials the following were prepared:

Example 836-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-pyrrolidin-1-ylethyl)naphthalene-2-sulfonamideformate

Mass spectrum: Found: MH⁺ 563

H.p.l.c. (1) Rt 2.58 min

Example 846-Chloro-N-[2-(dimethylamino)ethyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamideformate

Mass spectrum: Found: MH⁺ 537

H.p.l.c. (1) Rt 2.53 min

Example 85N-[2-([(6-Chloro-2-naphthyl)sulfonyl]{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}amino)ethyl]acetamide

Mass spectrum: Found: MH⁺ 551

H.p.l.c. (1) Rt 2.91 min

Example 865-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-1H-indole-2-sulfonamide

Intermediate 33 (0.011 g) was dissolved in 1:1 TFA/DCM (0.5 ml) andallowed to stand at room temperature for 1 h. The mixture wasconcentrated under reduced pressure and the residue partitioned betweensaturated aqueous sodium bicarbonate and DCM. The separated organicphase was dried (over magnesium sulphate) and concentrated under astream of nitrogen to give the title compound (0.0082 g) as white solid.

Mass spectrum: Found: MH⁺ 455

H.p.l.c. (1) Rt 2.97 min

Example 876-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-1,3-benzothiazole-2-sulfonamide

Intermediate 58 (0.1 g) was stirred at room temperature in anhydrousacetone (3 ml) and 5% aqueous potassium permanganate (1.35 ml) for 3 h,after which additional acetone (3 ml) and 5% aqueous potassiumpermanganate (1.35 ml) were added. The reaction mixture was stirred fora further 18 h and filtered through Celite™. The filtrate wasconcentrated under reduced pressure and the residue purified by massdirected preparative h.p.l.c to give the title compound (0.0062 g) as awhite solid.

Mass spectrum: Found: MH⁺ 473

H.p.l.c. (1) Rt 2.98 min

Example 886-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-(2-methylmorpholin-4-yl)-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide

To polymer N-cyclohexylcarbodiimide-N′-propyloxymethyl polystyrene(0.038 g) in an Alltech™ tube was added a solution of(2S)-2-((3S)-3-{[(6-chloro-2-naphthyl)sulfonyl]amino}-2-oxopyrrolidin-1-yl)propanoicacid (0.007 g) in DCM (0.9 ml) followed by 2-methylmorpholine (0.004 g)in DMF (0.1 ml) and N,N-diisopropylethylamine (0.006 ml). The mixturewas shaken at room temperature for 4 days. The tube was drained, thefiltrate collected and the resin washed with DCM. The combined DCMsolutions were concentrated under reduced pressure and the residuepurified by mass directed preparative h.p.l.c. to give the titlecompound (0.0038 g) as an off-white solid.

Mass spectrum: Found: MH⁺ 480

H.p.l.c. (1) Rt 3.17 min

Example 89(E)-2-(5-Chlorothien-2-yl)-N-methyl-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide

Sodium hydride (60% dispersion in oil, 0.011 g) was added totrimethysulphonium iodide (0.059 g) in dimethylsulphoxide (2 ml) between5-10° C., and the resultant mixture was stirred at room temperature for30 min. Example 61 (0.1 g) in dry THF (2 ml) was added between 5-10° C.,and the solution stirred at room temperature for 2.25 h, at 50° C. for70 h, cooled to room temperature and poured onto ice/water. The aqueousmixture was extracted with ethyl acetate and the combined, dried (overmagnesium sulphate) organic extracts were concentrated under reducedpressure. The residue was purified using mass directed preparativeh.p.l.c. to give the title compound (0.038 g) as a colourless oil.

Mass spectrum: Found: MH⁺ 462

H.p.l.c. (1) Rt 2.82 min

Example 906-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxopyrrolidinyl}thieno[3,2-b]pyridine-2-sulfonamide

The title compound was similarly prepared using Intermediate 40 and6-chlorothieno[3,2-b]pyridine-2-sulfonyl chloride, and the syntheticprocedure described for Example 386 (Route 1).

Mass spectrum: Found: MH⁺ 473

H.p.l.c. (I) Rt 2.61 min

Prepared according to the procedure described in U.S. Pat. No.6,281,227.

References

-   1. Klimkowski, Valentine Joseph; Kyle, Jeffrey Alan; Masters, John    Joseph; Wiley, Michael Robert. PCT Int. Appl. (2000), WO 0039092.-   2. Choi-Sledeski, Yong Mi; Pauls, Heinz W.; Barton, Jeffrey N.;    Ewing, William R.; Green, Daniel M.; Becker, Michael R.; Gong, Yong;    Levell, Julian. PCT Int. Appl. (1999), WO 9962904.    In Vitro Assay for Inhibition of Factor Xa

Compounds of the present invention were tested for their Factor Xainhibitory activity as determined in vitro by their ability to inhibithuman Factor Xa in a chromogenic assay, usingN-α-benzyloxycarbonyl-D-Arg-Gly-Arg-p-nitroanilide as the chromogenicsubstrate. Compounds were diluted from a 10 mM stock solution indimethylsulfoxide at appropriate concentrations. Assay was performed atroom temperature using buffer consisting of: 50 mM Tris-HCl, 150 mMNaCl, 5 mM CaCl2, pH 7.4, containing human Factor Xa (final conc. Of0.0015 U.ml-1). Compound and enzyme were preincubated for 15 min priorto addition of the substrate (final conc. of 200 μM). The reaction wasstopped after 30 min with the addition of soybean trypsin inhibitor orH-D-PHE-PRO-ARG-Chloromethylketone. BioTek EL340 or Tecan SpectraFluorPlus plate readers were used to monitor the absorbance at 405 nM. Toobtain IC50 values the data were analysed using ActivityBase® andXLfit®.

All of the synthetic Example compounds tested (Examples 1-52, 54-89)exhibited IC₅₀ values of less than 60 μM. Preferably compounds have anIC₅₀ value of less than 2 }M, more preferably compounds have an IC₅₀value of less than 0.1 μM.

Measurement of Prothrombin Time (PT)—Test 1

Blood was collected into a sodium citrate solution (ratio 9:1) to give afinal concentration of 0.38% citrate. Plasma was generated bycentrifugation of citrated blood samples at 1200×g for 20 min at 4° C.

The PT test was performed at 37° C. in plastic cuvettes containing amagnetic ball bearing. 50 μL of citrated plasma and either 25 μL of 2.8%DMSO for control or 25 μL of test compound (dissolved in DMSO anddiluted in water and 2.8% DMSO to give 0.4% DMSO final in assay) at aconcentration of 7-times the final desired concentration was pippettedinto each cuvette. This mixture was incubated for 1 min at 37° C. beforeadding 100 μL of thromboplastin mixture (comprising lyophilised rabbitthromboplastin and calcium chloride which was reconstituted in distilledwater as per manufacturer's [Sigma] instructions). On addition of thethromboplastin mixture, the timer was automatically started andcontinued until the plasma clotted. The time to clotting was recorded(normal range for human plasma is 10-13 seconds).

Method for Measurement of Prothrombin Time (PT)—Test 2

Blood is collected into a sodium citrate solution (ratio 9:1) to give afinal concentration of 0.38% citrate. Plasma is generated bycentrifugation of citrated blood samples at 1200×g for 20 min at 4° C.

The PT test is performed at 37° C. in plastic cassettes and using aMCA210 Microsample Coagulation Analyzer (Bio/Data Corporation). Forassay, 25 ul of plasma containing test compound at concentrationsranging from 0.1 to 100 uM (made from a 1 mM stock solution in 10% DMSOand plasma) and 25 ul of Thromboplastin C Plus (Dade Berhing) areautomatically injected into the cassette. Upon addition of theThromboplastin C Plus, the instrument determines and records the time toclot (normal range for human plasma is 10-13 seconds).

General Purification and Analylical Methods

Analylical HPLC was conducted on a Supelcosil LCABZ+PLUS column (3 μm,3.3 cm×4.6 mm ID) eluting with 0.1% HCO₂H and 0.01 M ammonium acetate inwater (solvent A), and 95% acetonitrile and 0.05% HCO₂H in water(solvent B), using the following elution gradient 0-0.7 minutes 0% B,0.7-4.2 minutes 0100% B, 4.2-5.3 minutes 100% B, 5.3-5.5 minutes 100→0%B at a flow rate of 3 ml/minutes (System 1). The mass spectra (MS) wererecorded on a Fisons VG Platform mass spectrometer using electrospraypositive ionisation [(ES+ve to give MH⁺ and M(NH₄)⁺ molecular ions] orelectrospray negative ionisation [(ES-ve to give (M-H)⁻ molecular ion]modes.

LC/MS System (3)

Method 2 was conducted on a Waters Xtera RP18 column (3 μm, 15 cm×2.1 mmID) eluting with solvent A (0.1% HCO2H and water) and solvent B (100%acetonitrile, 0.1% HCO2H and reserpine 2.5 μml-1) at 20° C. Thefollowing elution gradient was ran: 0-2.0 minutes 0% B; 2.0-18.0 minutes0-100% B; 18.0-20.0 minutes 100% B; 20.0-22.0 minutes 100-0% B;22.0-30.0 minutes 0% B, at a flow rate of 0.4 ml/minutes. The massspectra (MS) were recorded on a Micromass QTOF 2 spectrometer usingelectrospray positive ionisation [ES+ve to give MH+].

Note: The number given in brackets in the Examples and Intermediatesabove, e.g. H.p.l.c. (1), specifies the LC/MS method used.

¹H nmr spectra were recorded using a Bruker DPX 400 MHz spectrometerusing tetramethylsilane as the external standard.

Biotage™ chromatography refers to purification carried out usingequipment sold by Dyax Corporation (either the Flash 40i or Flash 150i)and cartridges pre-packed with KPSil.

Mass directed autoprep refers to methods where the material was purifiedby high performance liquid chromatography on a HPLCABZ+5 μm column (5cm×10 mm i.d.) with 0.1% HCO₂H in water and 95% MeCN, 5% water (0.5%HCO₂H) utilising the following gradient elution conditions: 0-1.0minutes 5% B, 1.0-8.0 minutes 5→30% B, 8.0-8.9 minutes 30% B, 8.9-9.0minutes 30→95% B, 9.0-9.9 minutes 95% B, 9.9-10 minutes 95→0% B at aflow rate of 8 ml minutes⁻¹ (System 2). The Gilson 202-fractioncollector was triggered by a VG Plafform Mass Spectrometer on detectingthe mass of interest.

Hydrpophobic frits refers to filtration tubes sold by Whatman.

SPE (solid phase extraction) refers to the use of cartridges sold byInternational Sorbent Technology Ltd.

TLC (thin layer chromatography) refers to the use of TLC plates sold byMerck coated with silica gel 60 F₂₅₄.

1. The present invention provides compounds of formula (I):

wherein: R¹ represents hydrogen, —C₁₋₆alkyl, —C₃₋₆alkenyl,—C₂₋₃alkylNR^(b)R^(c), —C₂₋₃alkylNHCOR^(b), phenyl or a 5- or 6-memberedaromatic heterocyclic group, the phenyl or 5- or 6-membered aromaticheterocyclic group being optionally substituted by halogen, or R¹represents a group X—W, wherein X represents —C₁₋₃alkylene- and Wrepresents —CN, —CO₂H, —CONR^(b)R^(c), —COC₁₋₆alkyl, —CO₂C₁₋₆alkyl,phenyl or 5- or 6-membered aromatic or non-aromatic heterocyclic groupcontaining at least one heteroatom selected from O, N or S, the phenylor aromatic heterocyclic group being optionally substituted by one ormore substitutents selected from: —C₁₋₃alkyl, —C₁₋₃alkoxy, —C₁₋₃alkylOH,halogen, —CN, —CF₃, —NH₂, —CO₂H and —OH; R² and R³ independentlyrepresent hydrogen, —C₁₋₃alkyl or —CF₃ with the proviso that one of R²and R³ is —C₁₋₃alkyl or —CF₃ and the other is hydrogen; R^(b) and R^(c)independently represent hydrogen or —C₁₋₃alkyl; A represents a groupselected from:

Z represents one or two optional substituents independently selectedfrom halogen and OH, W represents an optional substituent —C₁₋₃alkyl,alk represents C₂₋₃alkylene or C₂₋₃alkenylene, T represents a heteroatomselected from O, S or N; B represents one or more optional substituentson ring carbon atoms selected from: (i) one or more substituentsselected from —CF₃, —F, —CO₂H, —C₁₋₆alkyl, —C₁₋₆alkylOH,—(C₁₋₃alkyl)NR^(b)R^(c), —(C₀₋₃alkyl)CONR^(b)R^(c) and—(C₀₋₃alkyl)CO₂C₁₋₃alkyl, —CONHC₂₋₃alkylOH, —CH₂NHC₂₋₃alkylOH,—CH₂OC₁₋₃alkyl and —CH₂SO₂C₁₋₃alkyl; (ii) a group —Y—R^(e), Y represents—C₁₋₃alkylene-, —CO—, —C₁₋₃alkylNH—, —C₁₋₃alkylNHCO—, —C₁₋₃alkylNHSO₂—,—CH₂NHSO₂CH₂— or a direct link, R^(e) represents phenyl, a 5- or6-membered cycloalkyl or a 5- or 6-membered heterocycle containing atleast one heteroatom selected from O, N or S, each of which isoptionally substituted by one or more substituents selected from:—C₁₋₃alkyl, —C₁₋₃alkoxy, —C₁₋₃alkylOH, halogen, —CN, —CF₃, —NH₂, —CO₂Hand —OH; or (iii) a second ring R^(f) which is fused to the heterocyclicring, wherein R^(f) represents phenyl, a 5- or 6-membered cycloalkylgroup or a 5- or 6-membered aromatic heterocyclic group containing atleast one heteroatom selected from O, N or S, and the fused bicyclicgroup is optionally substituted by one or more substituents selectedfrom: —C₁₋₃alkyl, —C₁₋₃alkoxy, —C₁₋₃alkylOH, halogen, —CN, —CF₃, —NH₂,—CO₂H and —OH; and pharmaceutically acceptable derivatives thereof.
 2. Acompound as claimed in claim 1 having the formula (Ia):

wherein: R¹ represents hydrogen, —C₁₋₆alkyl, —C₂₋₆alkenyl or a groupX—W, wherein X represents —C₁₋₃alkylene- and W represents —CN, —CO₂H,—CONR^(b)R^(c), —COC₁₋₆alkyl, —CO₂C₁₋₆alkyl, phenyl or 5- or 6-memberedaromatic heterocyclic group containing at least one heteroatom selectedfrom O, N or S, the phenyl or aromatic heterocyclic group beingoptionally substituted by one or more substitutents selected from:—C₁₋₃alkyl, —C₁₋₃alkoxy, —C₁₋₃alkylOH, halogen, —CN, —CF₃, —NH₂, —CO₂Hand —OH; R² and R³ independently represent hydrogen, —C₁₋₃alkyl or —CF₃with the proviso that when one of R² and R³ is —C₁₋₃alkyl or —CF₃, theother is hydrogen; R^(b) and R^(c) independently represent hydrogen or—C₁₋₃alkyl; A represents a group selected from:

Z represents an optional substituent halogen, alk represents alkylene oralkenylene, T represents a heteroatom selected from S or N; B representsone or more optional substituents on ring carbon atoms selected from:(i) one or more substituents selected from —CF₃, —F, ═O, —CO₂H,—C₁₋₆alkyl, —C₁₋₆alkylOH, —(C₁₋₃alkyl)NR^(b)R^(c),—(C₀₋₃alkyl)CONR^(b)R^(c) and —(C₀₋₃alkyl)CO₂C₁₋₃alkyl; (ii) a group—Y—R^(e), Y represents —C₁₋₃alkylene-, —CO—, —C₁₋₃alkylNH—,—C₁₋₃alkylNHCO—, —C₁₋₃alkylNHSO₂—, —CH₂NHSO₂CH₂— or a direct link, R^(e)represents phenyl, a 5- or 6-membered cycloalkyl or a 5- or 6-memberedheterocycle containing at least one heteroatom selected from O, N or S,each of which is optionally substituted by one or more substituentsselected from: —C₁₋₃alkyl, —C₁₋₃alkoxy, —C₁₋₃alkylOH, halogen, —CN,—CF₃, —NH₂, —CO₂H and —OH; or (iii) a second ring R^(f) which is fusedto the heterocyclic ring, wherein R^(f) represents phenyl, a 5- or6-membered cycloalkyl group or a 5- or 6-membered aromatic heterocyclicgroup containing at least one heteroatom selected from O, N or S, andthe fused bicyclic group is optionally substituted by one or moresubstituents selected from: —C₁₋₃alkyl, —C₁₋₃alkoxy, —C₁₋₃alkylOH,halogen, —CN, —CF₃, —NH₂, —CO₂H and —OH; and pharmaceutically acceptablesalts and solvates thereof.
 3. A compound as claimed in claim 1 whereinR¹ represents hydrogen, —C₁₋₆alkyl, —C₃₋₆alkenyl, —C₂₋₃alkylNR^(b)R^(c),—C₂₋₃alkylNHCOR^(b), phenyl or a 5- or 6-membered aromatic heterocycle,or R¹ represents a group X—W wherein X represents —C₁₋₃alkylene- and Wrepresents —CN, —CO₂H, —CONR^(b)R^(c), —COC₁₋₆alkyl, —CO₂C₁₋₆alkyl, or a5- or 6-membered aromatic or nonaromatic heterocyclic group containingat least one heteroatom selected from O, N or S.
 4. A compound asclaimed in claim 1 wherein R² represents —C₁₋₃alkyl or hydrogen.
 5. Acompound as claimed in claim 1 wherein R³ represents —C₁₋₃alkyl orhydrogen.
 6. A compound as claimed in claim 1 wherein B representshydrogen or a substituent selected from —C₁₋₆alkyl, —CONHCH₃,—CONHCH₂CH(OH)CH₃, —CH₂NH(CH₃)₂, —CH₂OCH₃, —CH₂SO₂CH₃,—CH₂NHCH₂CH(OH)CH₃,


7. A compound as claimed in claim 1 wherein B represents hydrogen.
 8. Acompound as claimed in claim 1 wherein A represents a group selectedfrom


9. A compound as claimed in claim 1 selected from:(E)-2-(4-Chlorophenyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide,6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,5′-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-2,2′-bithiophene-5-sulfonamide,N2-{[(E)-2-(4-Chlorophenyl)ethenyl]sulfonyl}-N2-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinamide,N2-[(5′-Chloro-2,2′-bithien-5-yl)sulfonyl]-N2-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinamide,5′-Chloro-N-(cyanomethyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-2,2′-bithiophene-5-sulfonamide,MethylN-[(5′-chloro-2,2′-bithien-5-yl)sulfonyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinate,5′-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-oxobutyl)-2,2′-bithiophene-5-sulfonamide,N-[(5′-Chloro-2,2′-bithien-5-yl)sulfonyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycine,(E)-2-(4-Chlorophenyl)-N-(cyanomethyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide,(E)-2-(4-Chlorophenyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-oxobutyl)ethenesulfonamide,MethylN-{[(E)-2-(4-chlorophenyl)ethenyl]sulfonyl}-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinate,6-Chloro-N-(3-furylmethyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(pyridin-3-ylmethyl)naphthalene-2-sulfonamideformate,6-Chloro-N-ethyl-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-oxobutyl)naphthalene-2-sulfonamide,N-2-[(6-Chloro-2-naphthyl)sulfonyl]-N-2-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinamide,6-Chloro-N-(2-furylmethyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(1,3-thiazol-2-ylmethyl)naphthalene-2-sulfonamide,N2-[(6-Chloro-2-naphthyl)sulfonyl]-N2-((3S)-1-{(1S)-2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-1-methyl-2-oxoethyl}-2-oxopyrrolidin-3-yl)glycinamide,6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-[(2-methyl-1,3-thiazol-4-yl)methyl]naphthalene-2-sulfonamide,6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(pyridin-2-ylmethyl)naphthalene-2-sulfonamideformate,6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(pyridin-4-ylmethyl)naphthalene-2-sulfonamideformate,6-Chloro-N-(cyanomethyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,6-Chloro-N-methyl-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,6-Chloro-N-(3,3-dimethyl-2-oxobutyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,N-Allyl-6-chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide,MethylN-[(6-chloro-2-naphthyl)sulfonyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinate,tert-ButylN-[(6-chloro-2-naphthyl)sulfonyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinate,N-[(6-Chloro-2-naphthyl)sulfonyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycine,(E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide,6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-oxobutyl)-1-benzothiophene-2-sulfonamide,N2-[(6-Chloro-1-benzothien-2-yl)sulfonyl]-N2-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinamide,N2-[(6-Chloro-2-naphthyl)sulfonyl]-N2-((3S)-1-{(1S)-2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-1-methyl-2-oxoethyl}-2-oxopyrrolidin-3-yl}glycinamide,6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-morpholin-4-ylethyl)naphthalene-2-sulfonamideformate,6-Chloro-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-pyrrolidin-1-ylethyl)naphthalene-2-sulfonamideformate,6-Chloro-N-[2-(dimethylamino)ethyl]-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamideformate, andN-[2-([(6-Chloro-2-naphthyl)sulfonyl]{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}amino)ethyl]acetamide.10. (canceled)
 11. A pharmaceutical composition comprising a compoundaccording to claim 1 together with a pharmaceutical carrier and/orexcipient.
 12. (canceled)
 13. A method of treating a patient sufferingfrom a condition susceptible to amelioration by a Factor Xa inhibitorcomprising administering a therapeutically effective amount of acompound according to claim
 1. 14. A process for preparing a compound offormula (I), as defined in claim 1, which comprises: (a) reacting acompound of formula (II) with a compound of formula (III):

OR: (b) reacting a compound of formula (XV) with a compound of formula(VI):

OR: (c) reacting a compound of formula (XVI) with a compound of formula(VIII):